SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
______________________________________________________
FORM 10-K
[X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE
SECURITIES EXCHANGE ACT OF 1934 [FEE REQUIRED]
______________________________________________________
For the Year Ended December 31, 1998
Commission File Number 0-8640
SYNCOR INTERNATIONAL CORPORATION
(Exact name of registrant as specified in its charter)
Delaware 85-0229124
(State or other jurisdiction of I.R.S. Employer
incorporation or organization) Identification No.)
6464 Canoga Avenue, Woodland Hills, California 91367-2407
(Address of principal executive offices) (Zip Code)
(818) 737-4000
(Registrant's telephone number,
including area code)
Securities registered pursuant to Section 12(b) of the Act:
None
Securities registered pursuant to Section 12(g) of the Act:
COMMON STOCK $.05 PAR VALUE
(Title of Class)
Indicate by check mark whether the Registrant (1) has filed all
reports required to be filed by Section 13 or 15(d) of the
Securities Exchange Act of 1934 during the preceding 12 months
(or for such shorter period that the registrant was required to
file such reports), and (2) has been subject to such filing
requirements for the past 90 days. Yes X No
Indicate by check mark if disclosure of delinquent filers
pursuant to Item 405 of Regulations S-K (section 229.405 of this
chapter) is not contained herein, and will not be contained, to
the best of registrant's knowledge, in definitive proxy or
information statements incorporated by reference in Part III of
this Form 10-K or any amendment to this Form 10-K. ___
The aggregate market value of the voting stock held by
non-affiliates of the Registrant, computed by reference to the
average bid and asked prices of such stock on March 24, 1999 was
$294,096,531. For purposes of the foregoing calculation, each
executive officer and director of Registrant was deemed an
"affiliate" of Registrant. The number of shares outstanding
(excluding treasury shares) of the Registrant's $0.05 par value
common stock as of March 24, 1999 was 11,614,670 shares.
DOCUMENTS INCORPORATED BY REFERENCE
Portions of Registrant's Annual Report to Stockholders for the
year ended December 31, 1998, are incorporated by reference into
Parts I, II and IV of this report.
Portions of Registrant's definitive Proxy Statement for
Registrant's Annual Meeting of Stockholders on June 23, 1999, are
incorporated by reference into Part III of this report.
<PAGE>
SYNCOR INTERNATIONAL CORPORATION
TABLE OF CONTENTS
FORM 10-K ANNUAL REPORT
December 31, 1998
PART I Page
Item 1. BUSINESS..........................................1
Item 2. PROPERTIES.......................................10
Item 3. LEGAL PROCEEDINGS................................13
Item 4. SUBMISSION OF MATTERS TO A VOTE OF
SECURITY HOLDERS.................................13
PART II
Item 5. MARKET FOR REGISTRANT'S COMMON EQUITY
AND RELATED STOCKHOLDER MATTERS..................13
Item 6. SELECTED FINANCIAL DATA..........................13
Item 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS....13
Item 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES
ABOUT MARKET RISK................................14
Item 8. CONSOLIDATED FINANCIAL STATEMENTS
AND SUPPLEMENTARY DATA...........................14
Item 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON
ACCOUNTING AND FINANCIAL DISCLOSURE..............14
PART III
Item 10. DIRECTORS AND EXECUTIVE OFFICERS OF THE
REGISTRANT.......................................14
Item 11. EXECUTIVE COMPENSATION...........................14
Item 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS
AND MANAGEMENT...................................15
Item 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS...15
PART IV
Item 14. EXHIBITS, FINANCIAL STATEMENT SCHEDULES
AND REPORTS ON FORM 8-K..........................16
<PAGE>
PART I
Item 1. BUSINESS.
Unless otherwise indicated, the term "Syncor" or the "Company" as
used in this report refers to Syncor International Corporation,
incorporated in 1985 under the laws of the State of Delaware, and
its consolidated subsidiaries.
GENERAL DEVELOPMENT OF BUSINESS
The general development of the Company's business for the year
ended December 31, 1998, is covered in the letter from the
Chairman of the Board and the President and Chief Executive
Officer to the Company's stockholders in the Company's Annual
Report to Stockholders for said year and is incorporated into
this Form 10K by reference. A copy of the Company's Annual
Report to Stockholders is attached as Exhibit 13.
PRINCIPAL PRODUCTS PRODUCED AND SERVICES RENDERED
Pharmacy Services Business
The Company is primarily a pharmacy services company engaged in
compounding, dispensing and distributing radiopharmaceutical
products and services to hospitals and clinics through its
network of 120 nuclear pharmacy service centers in the United
States and 14 nuclear pharmacy service centers outside of the
United States. The Company's pharmacies process
radiopharmaceutical prescriptions in convenient packaging for the
customer, called "unit dose". The unit dose is then applied to a
specific patient for diagnostic imaging of physiological
functions and organ systems and for monitoring and treatment of
diseases.
The Company is also a distributor of imaging cold kits, or "bulk"
radiopharmaceutical vials, from which customers draw their own
unit doses. The Company's sales of bulk vials have steadily
decreased during the past three years as hospitals and clinics
increasingly convert to unit dose purchases. Bulk and unit dose
sales are discussed in more detail in the section entitled
"Competitive Conditions" below.
In addition, the Company provides various services in connection
with the sale of radiopharmaceuticals, including
radiopharmaceutical record keeping required by federal and state
government agencies, and radiopharmaceutical technical
consulting. The Company also markets and distributes isotopes,
medical reference sources, and nuclear and pharmacy equipment and
accessories. The Company estimates that its pharmacies serve
approximately 7,000 hospitals and clinics in 48 states throughout
the United States.
Medical Imaging Business
In 1998, the Company expanded its role in the field of medical
imaging by acquiring three medical imaging businesses. The
Company, through its subsidiary, Comprehensive Medical Imaging,
Inc. ("CMI") now wholly owns 19 medical imaging centers and
manages and partly owns an additional 18 medical imaging centers
located in 11 states and Puerto Rico. The centers are
concentrated primarily in California, Arizona, Virginia and
Florida. In addition, the Company owns a medical imaging center
in Auckland, New Zealand, and manages a hospital's medical
imaging department in Taiwan.
These medical imaging centers provide one or more outpatient and
inpatient diagnostic imaging services, including MRI (36
centers), computerized tomography or CT (9 centers), nuclear
imaging (3 centers), X-ray (4 centers), ultrasound (6 centers),
mammography (5 centers) and fluoroscopy (5 centers). The
Company's goal is to help customers become more efficient and
effective in meeting the demands of patients, physicians and
health plans for the production of more timely, accurate and
cost-effective diagnostic results across multiple modalities and
geographic markets. The medical services provided in each
imaging center are performed by groups of radiologists affiliated
with the Company. The radiologists interpret diagnostic images
and supervise technicians performing medical imaging procedures,
while the Company performs marketing, legal, billing and other
administrative and technical functions. Of the 18 partially-
owned centers, 15 are managed by TME, Inc., a subsidiary of CMI,
in exchange for a management fee.
CMI also operates a service called IMI-Net, a multi-state patient
referral network that contracts with insurance payers to arrange
the scanning of patients in medical imaging facilities certified
by IMI-Net to have met IMI-Net's level of quality standards.
Manufacturing Business
The Company, through its subsidiary, Syncor Pharmaceuticals,
Inc., manufactures Iodine-123 capsules in its manufacturing
facility in Golden, Colorado. An Iodine-123 capsule is a
radiopharmaceutical diagnostic product used for thyroid
disorders. Syncor Pharmaceuticals allows the Company to maintain
a reliable supply of Iodine-123 capsules for its customers and
their patients. In the future, the Company hopes to manufacture,
package and distribute other pharmaceutical products.
The description of the Company's various activities in the
Company's Annual Report to Stockholders for the year ended
December 31, 1998 is incorporated into this Form 10-K by
reference.
SOURCES AND AVAILABILITY OF RAW MATERIALS
The Company's pharmacies dispense approximately sixty different
radiopharmaceutical products, which are obtained primarily from
six suppliers. The Company's principal supplier of
radiopharmaceutical products is the Radiopharmaceutical Division
of The DuPont Pharmaceutical Company ("DuPont"), with whom the
Company has had a long-standing relationship with respect to the
distribution of its products, including its bulk
radiopharmaceutical products since February 1, 1994.
Cardiology sales constituted approximately 65 percent of the
Company's sales in 1998. Sixty seven percent of the cardiology
sales was derived from sales of Cardiolite(TM), a DuPont
cardiology product to which the Company has preferred
distribution rights.
If DuPont is not able to supply its proprietary products to the
Company, particularly Cardiolite(TM), the Company's operations
could be negatively impacted. Management believes, however, that
if DuPont or any of the other suppliers of proprietary
radiopharmaceuticals to the Company failed to supply products,
the Company's other current suppliers would be able to supply
additional products to make up most of the shortfall. The
failure of two or more suppliers to provide products at a
particular time, however, could have an adverse effect on the
Company's business.
The Company derives approximately 64 percent of its radiopharmacy
net sales per day from technetium-based products. The Company
obtains its supply of technetium, a radioactive isotope, from
technetium generators provided primarily by DuPont. Since
radioactive isotopes decay naturally, the Company cannot
stockpile technetium generators for use during temporary
shortages. DuPont's supply of technetium generators was
interrupted for approximately six days in May 1998 as a result of
a labor dispute experienced by its main supplier of molybdenum,
the parent isotope of technetium. The supply interruption did
not have a material impact on the Company's sales. A similar
interruption, however, depending on its duration, could have a
material adverse effect on the Company's business. In order to
prevent a similar interruption, DuPont is attempting to secure
alternative molybdenum sources.
The principal raw material used by the Company in its
manufacturing facility in Colorado is the radioactive isotope,
Iodine-123. The Company obtains its supply of Iodine-123 from
MDS Nordion, which has supplied the material without interruption
during the last six years.
The Company is consistently in pursuit of improving its
relationships with current suppliers and developing new long-term
relationships.
PATENTS, TRADEMARKS, AND LICENSES
The Company owns a number of trademarks and patents, including
patent rights to the SECURE Safety Insert System(TM), a safety
insert container system used for the safe delivery, handling and
disposal of unit dose products. The Company also has patent
rights to a family of radiopharmaceutical delivery systems
referred to as the "Pigs" (Piglet(TM), Piglet2(TM) and
PETPig(TM)). The Pigs are tungsten containers that weigh
considerably less than current lead containers and set new
industry standards for the safe transport and handling of
radioactive substances. They also provide enhanced radiation
shielding resulting in a reduction in radiation exposure to our
pharmacy personnel and customers.
The Company also licenses its proprietary Unit Dose Manager(TM),
NucLink(TM) and Windows-based SYNtrac(TM) integrated software and
hardware systems to its customers to assist in the management of
their nuclear medicine departments and to facilitate electronic
communication between the Company's local radiopharmacies and
customers. As of December 31, 1998, the Company had
approximately 1,434 customers who were active licensees of the
software systems. The foregoing trademarks, patents and licenses
are key components to the Company's ability to operate its
pharmacies efficiently, provide high quality customer service,
and build mutually beneficial long-term relationships with the
Company's customers.
DEPENDENCE ON CUSTOMERS
Pharmacy Services Customers
The Company has primarily two types of radiopharmacy customers.
The first type of customer is a corporate account customer, which
may be a national managed care provider or a group purchasing
organization ("GPO"). The corporate account customer owns,
manages or negotiates contracts for a network of hospitals and
clinics that purchase most of their radiopharmaceutical
requirements from the Company. In 1998, the Company's largest
corporate account customers included Columbia/HCA, AmeriNet,
Inc., Novation (the GPO representing VHA, Inc.), TENET, Health
Service Corporation of America and Kaiser Foundation Health Plan,
Inc. Sales to corporate account customers were valued at
approximately $146 million in 1998, representing nearly 35% of
the Company's total radiopharmacy sales, compared to $195 million
in 1997 representing 51% of the Company's 1997 radiopharmacy
sales. In 1998, sales to the Company's three biggest corporate
account customers (Novation, Columbia/HCA and AmeriNet) accounted
for approximately 81% of the total corporate account sales,
compared to 54% in 1997. The contrast between 1997 and 1998 can
be attributed primarily to the loss of the Premier contract in
1997; while Syncor continued to sell radiopharmaceuticals to
Premier's affiliates after the contract termination, Syncor no
longer classified those sales as corporate accounts sales.
The second type of customer is an individual hospital or clinic
that makes purchases from the Company independent of any
agreement with a national managed care provider or GPO. Sales to
non-corporate account customers were valued at approximately $250
million in 1998, representing nearly 63% of the Company's total
radiopharmacy sales, compared to $170 million in 1997
representing 45% of the Company's 1997 radiopharmacy sales.
The Company's radiopharmacy operations are such that none of its
business is dependent upon a single customer. If two or more
corporate account customers were to cause all or most of their
affiliated or member hospitals and clinics to cease using the
Company's services, it could result in a negative impact on the
Company's operations. If a corporate account customer terminates
its agreement with the Company, however, the Company's experience
has been that many of that customer's affiliated or member
hospitals and clinics will continue to do business with the
Company. They remain with the Company for one or more of the
following reasons: (i) the affiliated hospital or clinic may be
committed to purchase radiopharmaceuticals from the Company for a
set term, independent of its affiliation with the corporate
account customer; (ii) since the Company is the only true
nationwide distributor of radiopharmaceuticals, in several
markets the Company's radiopharmacy may be the only viable source
of radiopharmaceutical products and services; (iii) the Company
offers products and services that are not offered by competitors;
or (iv) the hospital or clinic prefers the service offered by the
Company over the service provided by a competitor.
In December 1998, the Company announced the termination of its
corporate accounts agreement with Novation effective March 1,
1999. The Company, however, expects to continue to provide
radiopharmaceutical products and services to many of Novation's
members and affiliates, just as the Company has been successful
in retaining as customers most of the hospitals and clinics
affiliated with Premier. The advantage to having a corporate
accounts agreement in place is that the affiliated hospitals and
clinics are more likely to be bound by long-term supply
agreements with the Company.
Medical Imaging Customers
The Company's ability to attract medical imaging customers
depends on many factors, including its ability to contract with
healthcare providers and payers and to attract referrals from
physicians representing various medical specialties, the type and
quality of equipment, and the quality and timeliness of test
results. Referrals may depend on the existence of a contractual
relationship between a center and a patient's insurance carrier
or between a center and a health care provider (such as a managed
care provider, hospital or clinic). The loss of one or a few
large customers would not have a material adverse effect on the
Company's business; however, such a loss could have a material
adverse impact on the local imaging centers operated by the
Company with whom such customers do business. Approximately 9.4%
of CMI's patient revenues are related to patients participating
in the Medicare and Medicaid programs. If CMI were to be
disqualified from participation in both the Medicare and Medicaid
programs, the resulting loss in revenues would have a material
adverse impact on CMI's business.
Manufacturing Customers
The Company's manufacturing facility in Colorado supplies almost
all of its Iodine-123 capsules to the Company's radiopharmacies.
The Company aims to expand the customer base for its Iodine-123
capsules.
COMPETITIVE CONDITIONS
Pharmacy Services Business
The nuclear medicine market is divided into two segments: the
market for bulk products and the market for unit dose products.
In 1998, the U.S. nuclear medicine market was valued at
approximately $840 million, with unit dose sales accounting for
approximately 80 percent of the market, and bulk product sales
accounting for the remaining 20 percent.
With respect to the bulk sales market, the Company competes with
radiopharmaceutical manufacturers that sell their products
directly to hospitals and clinics or indirectly through
radiopharmacies. The hospital or clinic, in turn, compounds the
bulk product into unit doses. Through its distribution
agreements with manufacturers, primarily with DuPont, the Company
is able to compete with manufacturers for bulk business.
The core of the Company's business, however, is in unit dose
sales, which generate higher profit margins than bulk sales. In
1998, the Company's unit dose sales represented 92 percent of the
Company's total radiopharmacy sales, an increase from 90 percent
in 1997. The Company's management believes that the advantages
to customers of using a centralized radiopharmacy to compound
unit doses rather than preparing their own radiopharmaceutical
products include: (i) reduced risk of radiation exposure to
hospital personnel; (ii) cost savings due to the Company's volume
purchasing power; (iii) better utilization of time-sensitive
products purchased from radiopharmaceutical manufacturers; (iv)
reduction in the time needed to maintain extensive records
required by regulatory agencies; and (v) elimination or reduction
of personnel, working space and equipment that would otherwise
have been necessary to compound unit doses.
The Company's radiopharmacies compete for unit dose sales with a
number of distributors, including two radiopharmaceutical
manufacturers that have also set up their own centralized
radiopharmacies to supply unit doses to customers, and
approximately 95 to 100 independent radiopharmacies located in
cities throughout the U.S. The advantages to operating an
independent radiopharmacy include lower start-up and overhead
costs and greater management flexibility. In certain markets,
there is competition with universities which own and operate
centralized radiopharmacies. The advantages to operating a
university radiopharmacy include having a guaranteed customer
base from the university's nuclear medicine department and having
access to subsidies from the university. In 1998, the Company
held approximately 50 to 55 percent of the market share for unit
dose sales.
The Company differentiates itself from its competitors, and adds
value to its customers, by providing, among other things: (i)
unit dose radiopharmaceuticals under rigorous quality control
standards; (ii) a comprehensive nuclear medicine product line;
(iii) professional consultation and delivery services; (iv) the
SECURE Safety Insert System(TM) and the Pigs system for the safe
delivery, handling and disposal of unit dose products; and (v)
the Unit Dose Manager(TM) and SYNtrac(TM) software and hardware
systems to allow customers to better manage their nuclear
medicine departments.
Medical Imaging Business
The Company's medical imaging centers compete with other
diagnostic imaging centers owned by physicians, hospitals, and
other medical imaging providers. The market is fragmented and
has no dominant national imaging services provider. There are
approximately 2,500 outpatient diagnostic imaging centers in the
U.S., and the largest provider owns approximately 5% of those
centers. The principal competitive factors are the quality and
timeliness of results, price, center location, type of equipment
available at the center, reputation of interpreting radiologists
and the center's ability to establish and maintain relationships
with health care providers and referring physicians. The Company
plans to enhance its network of referrals by building upon
existing relationships and developing new relationships through
the radiopharmacy business. The Company plans to differentiate
itself from the competition by becoming a regional leader in
providing medical diagnostic imaging services in selected
markets. Managed care entities and other payers increasingly
prefer to work with fewer providers of health care services,
including medical diagnostic imaging. Regional differentiation
combined with a complete offering of medical imaging services may
allow the Company to be the medical diagnostic imaging partner of
choice among regional payers seeking to minimize the number of
providers under contract.
GOVERNMENT REGULATION AND REIMBURSEMENT
Pharmacy Services and Manufacturing Business
Each of the Company's pharmacies is licensed by and must comply
with the regulations of the United States Nuclear Regulatory
Commission ("NRC") or corresponding state agencies. In addition,
each pharmacy is licensed and regulated by the Board of Pharmacy
in the state where it is located. The Company's manufacturing
facility in Colorado is licensed by the state of Colorado for
radioactive materials and is licensed by the Food and Drug
Administration ("FDA") as a manufacturing facility. The FDA also
inspects the facility for compliance with its "good manufacturing
practices" standards.
Periodic inspections of the Company's pharmacies are conducted by
the NRC and various other federal and state agencies.
Unsatisfactory inspection results could lead to escalated
enforcement action, the imposition of fines or the suspension,
revocation or denial of renewal of the licenses for the location
inspected. The Company devotes substantial human and financial
resources to ensure continued regulatory compliance and believes
that it is currently in material compliance with all material
rules and regulations.
The Company is subject to the various federal and state
regulations relating to occupational safety and health and the
use and disposal of bio-hazardous materials. In addition, the
Company's products are subject to federal and state regulations
relating to drugs and medical devices.
Compliance with the applicable environmental control laws and
regulations, such as those regulating the use and disposal of
radioactive materials, is inherent in the industry and the normal
operations of the Company's pharmacies and its manufacturing
facility. Historically, compliance with such laws and
regulations has not had a material adverse effect on the capital
expenditures, earnings or competitive position of the Company.
Medical Imaging Business
The federal government and all states in which the Company
operates or plans to operate medical imaging centers regulate
various aspects of the medical imaging business. Failure to
comply with these laws and regulations could have an adverse
impact on the Company's ability to receive reimbursement for its
services from government agencies and could also result in civil
and criminal penalties against the Company and its management.
Reimbursement for medical imaging may be undergoing change as
third-party payers, such as Medicare and Medicaid, health
maintenance organizations and other health insurance carriers,
increase efforts to control the cost, utilization and delivery of
healthcare services. Legislation has been proposed or enacted at
both the federal and state levels to regulate healthcare delivery
in general and radiology services in particular. Proposed
Medicare rules which were published in the summer of 1998, if
left unchanged, would have resulted in reductions in
reimbursement by HCFA for diagnostic imaging services over a
four-year phase-in period. In December of 1998, the onset of
such reductions, if any, was delayed until at least November of
1999. The final outcome to the proposed fee restructuring and
the impact on diagnostic facilities, and on the Company, cannot
be predicted at this time.
The medical imaging business is subject to state insurance laws
governing the presentation and payment of insurance claims for
medical imaging services to patients with health insurance. The
Company believes that it is in material compliance with such
laws.
The establishment and operation of outpatient diagnostic imaging
centers are subject to various licensure requirements. Some
states require a Certificate of Need ("CON") in certain
circumstances to establish, construct, acquire or expand
healthcare facilities and services. The Company may also have to
comply with federal certification requirements, such as the
federal certification requirement to provide mammography
examinations. The Company's imaging centers are also subject to
federal and state regulations relating to testing standards,
personnel accreditation and compliance with government
reimbursement programs.
The Federal Medicare and Medicaid Anti-Kickback Statute and
similar state statutes prohibit the offering, payment,
solicitation or receipt of any form of remuneration in return for
the referral of Medicare or Medicaid patients or patient care
opportunities, or in return for the purchase, lease or order or
provision of any item or service that is covered by Medicare or
Medicaid. Violations of the Anti-Kickback Statute or similar
state statutes could result in substantial civil and/or criminal
penalties in connection with willful violations of the statutes.
Violations could also result in the Company's exclusion from
Medicare or Medicaid programs. The Company believes that its
medical imaging centers are in material compliance with the Anti-
Kickback Statute and similar state statutes.
The Federal False Claims Act and similar state statutes prohibit
the presentation of a claim for payment under Medicare, Medicaid
and other federally funded programs containing false or
misleading information. Violations of the False Claims Act can
result in civil penalties of between $5,000 and $10,000 per false
claim plus treble damages. The Company believes that its medical
imaging centers are in material compliance with the False Claims
Act.
The "Stark II" statute, enacted under the Omnibus Budget
Reconciliation Act of 1993, prohibits a physician from making a
referral to an entity for the furnishing of designated health
services (including diagnostic imaging services) for which
Medicare may otherwise pay, if the physician has a financial
relationship with that entity. The regulations governing "Stark"
were finalized in 1998. In addition, a number of states
(including California and Florida) have enacted their own
versions of self-referral laws similar to Stark. The Company
believes that it is currently in material compliance with Stark
and similar statutes.
The medical imaging business may be subject to the laws of
certain states which prohibit the practice of medicine by non-
physicians and/or the splitting of fees between physicians and
non-physicians. The Company believes its operations are
conducted in material compliance with existing applicable laws
relating to the corporate practice of medicine and fee splitting.
The Company is also subject to licensing and regulation under
federal and state laws relating to the handling and disposal of
medical specimens, infectious and hazardous waste and radioactive
materials as well as to the safety and health of laboratory
employees. The sanctions for failure to comply with these
regulations may include denial of the right to conduct business,
significant fines and criminal penalties. The Company believes
that it is in material compliance with all such applicable laws
and regulations.
FOREIGN OPERATIONS
As of December 31, 1998, the Company owned and operated nuclear
pharmacy service centers in a total of thirteen foreign markets:
Hong Kong, S.A.R. (China); Taipei, Taichung and Kaoshiung
(Taiwan); Manila (Philippines); Bangkok (Thailand); Seoul (South
Korea); Sydney and Perth (Australia); Mexico City (Mexico);
Bogota (Colombia); San Juan (Puerto Rico); and Johannesburg
(South Africa). The Company also participates as a majority
equity holder in two nuclear pharmacy service center joint
ventures in Beijing and Shanghai. In 1998, the Company entered
into two additional joint ventures for Chengdu and Guangzhou
(China), and also entered into a technology license agreement to
establish a service center in Tel Aviv (Israel). In the first
quarter of 1998, the Company acquired a medical imaging center in
Puerto Rico, and in December 1998 opened a medical imaging center in
Auckland, New Zealand. Additional nuclear pharmacies and medical imaging
centers in foreign sites are being considered for development.
The Company recently expanded its business to provide management
services in the field of nuclear medicine and medical imaging. In
1998, the Company began managing two additional nuclear medicine
departments within hospitals in Taipei (Taiwan), in addition to
the nuclear medicine department it already manages in Chia-Yi
City (Taiwan). In early 1999, the Company also began to manage
the medical imaging department of the same hospital in Chia-Yi
City. In conjunction with another local hospital in Taipei, the
Company has also begun the build out of a cyclotron facility that
will produce positron emission tomography (PET)
radiopharmaceuticals.
The Company's foreign operations are not immune to the inherent
uncertainties and risks of currency fluctuations, political and
civil unrest, trade restrictions, and inconsistent market and
regulatory conditions.
EMPLOYEES
As of December 31, 1998, the Company employed almost 2,900 people
in the United States, of whom approximately 1,900 were full-time
employees.
Item 2. PROPERTIES.
The Company's corporate headquarters is located in Woodland
Hills, California. The Company leases approximately 60,967
square feet at that location, which is adequate for the Company's
current needs. The lease is for a term of ten years commencing
on March 1, 1997, with one five-year renewal option. The Company
also leases an administrative office facility in Duluth, Georgia.
The Company leases approximately 19,666 square feet at that
location, which is adequate for the Company's current needs. The
lease is for a term of ten years commencing on October 18, 1996.
<TABLE>
<CAPTION>
The Company and its consolidated subsidiaries lease (and in one location own)
and operate a number of pharmacies whose locations are set forth in the
following table*:
<S> <C> <C> <C>
STATE LOCATION STATE LOCATION
ALABAMA Birmingham NEBRASKA Lincoln
Mobile Omaha
ARIZONA Gilbert (Mesa) NEVADA Las Vegas
Phoenix Reno
Tucson NEW JERSEY Kenilworth (Newark)
ARKANSAS Jonesboro NEW MEXICO Albuquerque
Little Rock NEW YORK The Bronx
CALIFORNIA Bakersfield Cheektowaga (Buffalo)
Berkeley Franklin Square (Long Island)
Colton Newburgh
Fresno Rochester
Modesto Syracuse
Redding Troy (Albany)
Sacramento NORTH CAROLINA Charlotte
San Diego Greensboro
San Jose OHIO Cincinnati
Torrance Columbus
Van Nuys (Los Angeles) Girard (Youngstown)
COLORADO Colorado Springs Holland (Toledo)
Denver Miamisburg (Dayton)
CONNECTICUT Glastonbury (Hartford) Uniontown/Green (Akron)
Stamford Valley View (Cleveland)
DELAWARE Seaford OKLAHOMA Oklahoma City
FLORIDA Fort Myers Tulsa
Gainesville OREGON Portland
Jacksonville PENNSYLVANIA Allentown
Jupiter (West Palm Bloomsburg
Beach) Bristol (N. Philadelphia)
Miami Lakes (Miami) Erie
Pensacola Hummelstown (Harrisburg)
Pompano Beach (Ft. Pittsburgh
Lauderdale) Sharon Hill (Philadelphia)
Sarasota RHODE ISLAND Providence
Tampa SOUTH CAROLINA Columbia
Winter Park (Orlando) TENNESSEE Chattanooga
GEORGIA Augusta Jackson
Columbus Knoxville
Doraville (Atlanta) Memphis
Rome Nashville
ILLINOIS Chicago TEXAS Amarillo
Springfield Austin
INDIANA Ft. Wayne** Beaumont
Griffith Corpus Christi
Indianapolis Dallas
IOWA Des Moines El Paso
KANSAS Wichita Fort Worth
KENTUCKY Lexington Houston
Louisville Lubbock
LOUISIANA New Orleans San Antonio
MARYLAND Silver Springs VIRGINIA Richmond
Timonium (Baltimore) Virginia Beach
MASSACHUSETTS Woburn (Boston) WASHINGTON Seattle
MICHIGAN Grand Rapids Spokane
Southfield (Detroit) Tacoma
Swartz Creek (Flint) WEST VIRGINIA Huntington
MINNESOTA Moorhead (Fargo, ND) WISCONSIN Appleton (Green Bay)
St. Paul Wauwatosa (Milwaukee)
MISSISSIPPI Flowood (Jackson)
Tupelo
MISSOURI Kansas City
Overland (St. Louis)
Springfield
</TABLE>
* The Company also owns an interest in pharmacies in: Salt Lake City, Utah;
Midland, Texas; and Huntsville, Alabama.
** Managed by, and under the name of, Spectrum Pharmacy, Inc.
Pharmacy lease terms vary from less than one year to approximately ten years,
and average approximately five years. Leased areas average approximately
4,500 square feet.
CMI has its corporate headquarters in Westlake Village, California and also
has regional offices in Houston, Texas and Boca Raton, Florida. CMI owns or
manages medical imaging centers in various locations throughout the U.S. The
following table lists the medical imaging centers and describes CMI's
ownership interest in each center and the types of imaging modalities
offered in each center:
<TABLE>
<CAPTION>
NAME OF CENTER LOCATION PROPERTY OWNER- MODALITIES
SHIP
<S> <C> <C> <C> <C>
Anaheim Cath Lab * Anaheim, CA N/A 0 Catheterization Laboratory
Bakersfield Cath Lab * Bakersfield, CA N/A 0 Catheterization Laboratory
Boston Avenue Imaging Altamonte Leased 6.34 MRI/CT/Fluoroscopy/
Springs, FL Mammography/Ultrasound
Comprehensive OPEN MRI Bakersfield, CA Leased 100 MRI
-Bakersfield
Comprehensive OPEN MRI Dallas, TX Leased 100 MRI
-Dallas
Comprehensive OPEN MRI Encino, CA Leased 50 MRI
-Encino
Comprehensive OPEN MRI Fullerton, CA Leased 50 MRI
-Fullerton
Comprehensive OPEN MRI Laguna Hills, CA Leased 100 MRI
-Laguna Hills
Comprehensive OPEN MRI Plano, TX Leased 50 MRI
-Plano
Comprehensive OPEN MRI Sacramento, CA Leased 100 MRI
-Sacramento
Comprehensive Medical Fairfax, VA Leased 100 MRI/CT/Nuclear Medicine/
Imaging -Fairfax Fluoroscopy/Mammography
Corona Inland MRI Corona, CA Leased 100 MRI
Crescent City MRI New Orleans, LA Leased 26.08 MRI
Desert CT/MRI Palm Springs, CA Leased 100 MRI/CT
Desert CT/MRI Rancho Mirage, CA Leased 100 MRI/CT
Fairfield Cath Lab* Fairfield, CA N/A 0 Catheterization Laboratory
Fox Valley Imaging Naperville, IL Leased 6.37 MRI/CT/X-ray
Greenville MRI Greenville, NC Leased 32.22 MRI
Huntington Plaza MRI * Pasadena, CA N/A 0 MRI
IMI of Arlington Arlington, VA Leased 100 MRI
IMI of Boca Raton Boca Raton, FL Owned 100 MRI/CT/X-ray
IMI Diagnostic Center Plantation, FL Leased 100 CT/Mammography/X-ray/
Ultrasound/Nuclear
Medicine/Tomography
IMI of Kansas City Overland Park, KS Owned 100 MRI
IMI of Miami Miami, FL Leased 100 MRI/CT/X-ray/Fluoroscopy/
Ultrasound/Mammography
IMI of North Miami Beach North Miami Leased 100 MRI/Ultrasound
Beach, FL
IMI of Oakland Park Oakland Park, FL Leased 100 MRI
IMI of Pine Island Plantation, FL Owned 100 MRI
IMI of San Juan Santurce, Puerto Owned 100 MRI
Rico
Inland Imaging Associates Upland, CA Leased 6.34 MRI
Jefferson Imaging - Bala Bala Cynwyd, PA Leased 6.37 MRI
Jefferson Imaging - Langhorne, PA Leased 6.34 MRI
Langhorne
Lodi CT-MRI * Lodi, CA N/A 0 CT
Lodi Imaging Center * Lodi, CA N/A 0 Catheterization Laboratory/Nuclear
Medicine/Ultrasound/X-ray
Los Gatos MRI Los Gatos, CA Leased 16.80 MRI
MRI of Woodbridge Woodbridge, VA Leased 6.37 MRI
Medical Imaging Center of W. Orange, NJ Leased 14.80 MRI/CT/Ultrasound/
the Oranges Mammography/Fluoroscopy
Mesa MRI Mesa, AZ Leased 6.37 MRI
Mid States Diagnostic Wichita, KS N/A 0 Ultrasound/Nuclear Medicine
Services*
Mountain View MRI Paradise Valley, AZ Leased 6.34 MRI
Riverside MRI Center Riverside, CA Leased 6.35 MRI/Fluoroscopy
Tampa Diagnostic Institute Tampa, FL Leased 6.37 MRI
Thunderbird MRI Glendale, AZ Leased 100 MRI
Valley MRI Phoenix, AZ Leased 59.16 MRI
<PAGE>
West Coast Radiology Santa Ana, CA N/A 0 MRI/CT/Mammography/Ultrasound/
Center* Nuclear Medicine/X-ray/Bone
Density Testing/Radiation
Therapy
Wichita Diagnostic Wichita, KS Leased 100 MRI
Services
</TABLE>
* The Company receives a management fee for financial and accounting services
from these 8 medical imaging centers.
In addition to the listed imaging centers, the Company receives a fee for
managing the equipment leases in 11 other medical imaging centers.
<PAGE>
Item 3. LEGAL PROCEEDINGS.
The Company and its subsidiaries are involved in various
litigation proceedings. Many of the claims asserted against the
Company in these proceedings are covered by insurance. The
results of litigation proceedings cannot be predicted with
certainty. In the opinion of the Company's General Counsel,
however, such proceedings either are without merit or do not have
a potential liability which would materially affect the financial
condition of the Company and its subsidiaries on a consolidated
basis.
Item 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS.
None.
PART II
Item 5. MARKET FOR REGISTRANT'S COMMON EQUITY AND RELATED
STOCKHOLDER MATTERS.
The information relating to the Company's Common Stock which
appears in the Company's Annual Report to Stockholders for the
year ended December 31, 1998, under "Selected Quarterly Results
of Operations" and "Stockholder Information," included in this
Form 10-K Annual Report as Exhibit 13, is incorporated by
reference.
Item 6. SELECTED FINANCIAL DATA.
The selected financial data which appears in the Company's Annual
Report to Stockholders for the year ended December 31, 1998,
under the heading of "Selected Financial Data," included in this
Form 10-K Annual Report as Exhibit 13, are incorporated by
reference.
Item 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATIONS.
Management's discussion and analysis of financial condition and
results of operations which appears in the Company's Annual
Report to Stockholders for the year ended December 31, 1998,
under the heading of "Management's Discussion and Analysis of
Financial Condition and Results of Operations," included in this
Form 10-K Annual Report as Exhibit 13, is incorporated by
reference.
Item 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.
The quantitative and qualitative disclosures about market risk which
appear in the Company's Annual Report to Stockholders for the year
ended December 31, 1998, under the heading of "Quantitative and
Qualitative Disclosures About Market Risk," included in this Form
10-K Annual Report as Exhibit 13, are incorporated by reference.
Item 8. CONSOLIDATED FINANCIAL STATEMENTS AND SUPPLEMENTARY
DATA.
The consolidated financial statements and the notes thereto which
appear in the Company's Annual Report to Stockholders for the
year ended December 31, 1998, under the headings of "Consolidated
Statements of Income" and "Consolidated Balance Sheets," included
in this Form 10-K Annual Report as Exhibit 13, are incorporated
by reference. Schedules containing certain supporting
information are also included. See Financial Statement Schedules
on page 16 hereof.
Item 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON
ACCOUNTING AND FINANCIAL DISCLOSURE.
None.
PART III
Item 10. DIRECTORS AND EXECUTIVE OFFICERS OF THE REGISTRANT.
The information called for by Item 10 of Form 10-K is
incorporated by reference from the Company's definitive Proxy
Statement for its Annual Meeting of Stockholders, to be held on
June 23, 1999, which will be filed with the Commission pursuant
to Regulation 14A of the Securities and Exchange Commission
(Regulation 14) within 120 days from December 31, 1998.
Based solely upon its review of Forms 3, 4 and 5 furnished to the
Company, the Company believes that all reports required to be
filed during 1998 pursuant to Section 16(b) of the Securities
Exchange Act of 1934 were timely filed, except that Robert
Funari, Monty Fu, Haig Bagerdjian, Paul (Brad) Nutter, Michael
Mikity, John Baumann, Jack Coffey and Sheila Coop were late in
filing their respective Forms 4 for December 1998 to report the
vesting of performance rights granted under the Company's Long-
Term Performance Equity Plan for executive officers. The
Company's legal department typically prepares the Forms 3, 4 and
5 on behalf of the executive officers.
Item 11. EXECUTIVE COMPENSATION.
The information called for by Item 11 of Form 10-K is hereby
incorporated by reference from the Company's definitive Proxy
Statement for its Annual Meeting of Stockholders to be held on
June 23, 1999, which will be filed with the Commission pursuant
to Regulation 14A within 120 days from December 31, 1998.
Item 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND
MANAGEMENT.
The information called for by Item 12 of Form 10-K is hereby
incorporated by reference from the Company's definitive Proxy
Statement for its Annual Meeting of Stockholders to be held on
June 23, 1999, which will be filed with the Commission pursuant
to Regulation 14A within 120 days from December 31, 1998.
Item 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS.
The information called for by Item 13 of Form 10-K is hereby
incorporated by reference from the Company's definitive Proxy
Statement for its Annual Meeting of Stockholders to be held on
June 23, 1999, which will be filed with the Commission pursuant
to Regulation 14A within 120 days from December 31, 1998.
PART IV
Item 14. EXHIBITS, FINANCIAL STATEMENT SCHEDULES AND REPORTS
ON FORM 8-K.
(a) 1. Consolidated Financial Statements.
The consolidated financial statements listed
below, together with the report thereon of KPMG LLP, dated
February 22, 1999, which appear in the Company's Annual Report to
Stockholders for the year ended December 31, 1998, included in
this Form 10-K Annual Report as Exhibit 13, are hereby
incorporated herein by reference.
Independent Auditors' Report
Consolidated Balance Sheets
Consolidated Statements of Income
Consolidated Statements of Stockholders' Equity
Consolidated Statements of Cash Flows
Notes to Consolidated Financial Statements
2. Financial Statement Schedules.
The following schedule supporting the financial
statements of the Company is included herein:
Page
Schedule II Valuation and Qualifying Accounts 19
All other schedules and financial statements of
the Company are omitted because they are not applicable, not
required or because the required information is included in the
consolidated financial statements or notes thereto.
3. Index to Exhibits.
The list of exhibits filed as part of this
report on Form 10-K or incorporated by reference appears as Index
to Exhibits on page 20.
(b) Reports on Form 8-K filed in the Quarter Ended
December 31, 1998.
None.
(c) Exhibits.
The exhibits required by Item 601 of Regulation S-K
are filed with this Form 10-K Annual Report or are incorporated
by reference and are listed in the Index to Exhibits on page 20.
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the
Securities Exchange Act of 1934, the Registrant has duly caused
this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
SYNCOR INTERNATIONAL CORPORATION
By /s/ Robert G. Funari
Robert G. Funari
President and
Chief Executive Officer
Date: March 31, 1999
Pursuant to the requirements of the Securities Exchange Act of
1934, this report has been signed below by the following persons
on behalf of the Registrant and in the capacities and on the
dates indicated.
/s/ Monty Fu
Monty Fu, Chairman of the Board and Director
Date: March 31, 1999
/s/ Robert G. Funari
Robert G. Funari, President, Chief Executive Officer
(Principal Executive Officer) and Director
Date: March 31,1999
/s/ Brad Nutter
Brad Nutter, Executive Vice President and
Chief Operating Officer
Date: March 31, 1999
/s/ Haig S. Bagerdjian
Haig S. Bagerdjian, Executive Vice President,
Chief Legal Officer and Secretary
Date: March 31,1999
/s/ Michael E. Mikity
Michael E. Mikity, Senior Vice President,
Chief Financial Officer and Treasurer (Principal Financial and
Accounting Officer)
Date: March 31, 1999
/s/ George S. Oki
George S. Oki, Director
Date: March 31, 1999
/s/ Arnold E. Spangler
Arnold E. Spangler, Director
Date: March 31, 1999
/s/ Steven B. Gerber, M.D.
Steven B. Gerber, M.D., Director
Date: March 31, 1999
/s/ Henry N. Wagner, Jr., M.D.
Henry N. Wagner, Jr., M.D., Director
Date: March 31, 1999
/s/ Gail R. Wilensky
Dr. Gail R. Wilensky, Director
Date: March 31, 1999
/s/ Ronald A. Williams
Ronald A. Williams, Director
Date: March 31, 1999
SYNCOR INTERNATIONAL CORPORATION AND SUBSIDIARIES
Schedule II. Valuation and Qualifying Accounts
<TABLE>
<CAPTION>
(In thousands)
Balance Costs Balance
at and at
Beginning Expenses Deductions End of
Description of Period (A) (B) Period
<S> <C> <C> <C> <C>
Year Ended
December 31, 1998
Allowance for
doubtful accounts $1,040 $3,009 $ 275 $3,774
Year Ended
December 31, 1997
Allowance for
doubtful accounts $ 911 $ 0 $ (129) $1,040
Year Ended
December 31, 1996
Allowance for
doubtful accounts $1,097 $ 0 $ 186 $ 911
(A) Amount due to acquisition of medical imaging businesses and
related accounts receivable.
(B) Uncollectible accounts written-off, net of recoveries and
change in reserve.
</TABLE>
INDEX TO EXHIBITS
Exhibit No.
3. Certificate of Incorporation and By-Laws
3.1 Restated Certificate of Incorporation of the Company filed
as Exhibit 3.1 to the Form 10-K for the year ended May 31, 1987,
and incorporated herein by reference.
3.2 Restated By-Laws of the Company, filed as Exhibit 3.2 to
the Form 10-K for the year ended December 31, 1995, and
incorporated herein by reference.
4. Instruments Defining the Rights of Security Holders
4.1 Stock Certificate for Common Stock of the Company filed as
Exhibit 4.1 to the Form 10-K for the year ended May 31, 1986, and
incorporated herein by reference.
4.2 Rights Agreement dated as of November 8, 1989 between the
Company and American Stock Transfer & Trust Company filed as
Exhibit 2.1 to the Registration Statement on Form 8-A dated
November 3, 1989, and incorporated herein by reference.
10. Material Contracts
10.1 Syncor International Corporation 1981 Master Stock Option
Plan, as amended, filed as part of the Company's Proxy Statement
dated November 5, 1985, for its Annual Meeting of Stockholders
held November 26, 1985, and incorporated herein by reference.*
10.2 Form of Indemnity Agreement substantially as entered into
between the Company and each Director and Officer, filed as
Exhibit 3.2 Appendix A to the Form 10-K for the year ended
December 31, 1995, and incorporated herein by reference.*
10.3 Form of Benefits Agreement substantially as entered into
between the Company and each Director, filed as Exhibit 10.8 to
the Form 10-K for the year ended December 31, 1995, and
incorporated herein by reference.*
10.4 Form of Benefits Agreement substantially as entered into
between the Company and certain employees, filed as Exhibit 10.8
to the Form 10-K for the year ended December 31, 1995, and
incorporated herein by reference.*
10.5 Syncor International Corporation 1990 Master Stock
Incentive Plan, as amended and restated as of June 18, 1997,
filed as Exhibit 10.1 to the Company's Form 10-Q for the quarter
ended June 30, 1997, and incorporated herein by reference.*
10.6 Form of Stock Option Agreement substantially as entered
into between the Company and certain employee Directors and
employees filed as Exhibit 10.15 to the Form 10-K for year ended
December 31, 1993, and incorporated herein by reference.*
10.7 Form of Stock Option Agreement substantially as entered
into between the Company and certain non-employee Directors filed
as Exhibit 10.16 to the Form 10-K for the year ended December 31,
1993, and incorporated herein by reference.*
10.8 Non-Employee Director 1995 Stock Incentive Award
Agreement dated January 24, 1995 entered into between the Company
and Arnold E. Spangler, filed as Exhibit 10.17 to the Form 10-K
for the year ended December 31, 1995, and incorporated herein by
reference.*
10.9 Non-Employee Director 1995 Stock Incentive Award
Agreement dated January 24, 1995 entered into between the Company
and George S. Oki, filed as Exhibit 10.18 to the Form 10-K for
the year ended December 31, 1995, and incorporated herein by
reference.*
10.10 Non-Employee Director 1995 Stock Incentive Award
Agreement dated January 24, 1995 entered into between the Company
and Henry Wagner, Jr., filed as Exhibit 10.19 to the Form 10-K
for the year ended December 31, 1995, and incorporated herein by
reference.*
10.11 Non-Employee Director 1995 Stock Incentive Award
Agreement dated April 29, 1996, entered into between the Company
and Gail Wilensky, filed as Exhibit 4.3(b) to the Registration
Statement on Form S-8 filed on December 20, 1996 to register the
shares underlying said Award Agreement, and incorporated herein
by reference.*
10.12 Non-Employee Director 1995 Stock Incentive Award
Agreement dated April 29, 1996, entered into between the Company
and Steven Gerber, filed as Exhibit 4.3(a) to the Registration
Statement on Form S-8 filed on December 20, 1996 to register the
shares underlying said Award Agreement, and incorporated herein
by reference.*
10.13 Subscription Agreement, dated July 15, 1996, executed by
Syncor Management Corporation in favor of American Tax Credit
Corporate Fund III, L.P., together with a Promissory Note, dated
July 15, 1996, executed by Syncor Management Corporation in favor
of John Hancock Mutual Life Insurance Company, as assignee of
Corporate Credit, Inc., and the Guarantee of Parent Corporation,
dated July 15, 1996, executed by the Company in favor of John
Hancock Mutual Life Insurance Company, as assignee of Corporate
Credit, Inc. These agreements were filed as Exhibit 10.15 to the
Form 10-K for the year ended December 31, 1996, and are
incorporated herein by reference.
10.14 The 1996 Management Incentive Plan of the Company, filed
as Exhibit 10.3 to the Form 10-Q for the quarter ended September
30, 1996, and incorporated herein by reference.*
10.15 The 1997 Management Incentive Plan of the Company, filed
as Exhibit 10.18 to the Form 10-K for the year ended December 31,
1996, and incorporated herein by reference.*
10.16 The Office Lease, dated as of September 30, 1996, between
Massachusetts Life Insurance Company and the Company, relating to
the office lease for the Company's corporate headquarters in
Woodland Hills, California, filed as Exhibit 10.19 to the Form
10-K for the year ended December 31, 1996, and incorporated
herein by reference.
10.17 Lease, dated May 30, 1996, between the Company and
Technology Park/Atlanta, Inc., relating to the office lease for
the Company's administrative office in Duluth, Georgia, filed as
Exhibit 10.20 to the Form 10-K for the year ended December 31,
1996, and incorporated herein by reference.
10.18 Non-employee Director Stock Compensation Plan, dated
August 27, 1996, filed as Exhibit 4.3 to the Form S-8
Registration Statement filed by the Company with the SEC on
December 20, 1996.*
10.19 Loan Agreement, dated March 31, 1997, among Syncor
Pharmaceuticals, Inc., as borrower, the Company, as guarantor,
and The First National Bank of Chicago, as lender, filed as
Exhibit 10.1 to the Form 10-Q for the quarter ended March 31,
1997, and incorporated herein by reference.
10.20 Credit Agreement, dated August 8, 1997, between Syncor
International Corporation and Mellon Bank, N.A., filed as Exhibit
10.2 to the Form 10-Q for the quarter ended September 30, 1997,
and incorporated herein by reference.
10.21 Syncor International Corporation Deferred Compensation
Plan effective January 1, 1998, filed as Exhibit 10.24 to the
Form 10-K for the year ended December 31, 1997, and incorporated
herein by reference.*
10.22 Consulting Agreement, dated January 31, 1998, between
James F. Mitchell and the Company, filed as Exhibit 10.25 to the
Form 10-K for the year ended December 31, 1997, and incorporated
herein by reference.*
10.23 Credit Agreement, dated as of January 5, 1998, among the
Company, as borrower, The First National Bank of Chicago, as
lender and administrative agent, and Mellon Bank, N.A., as
lender, filed as Exhibit 10.26 to the Form 10-K for the year
ended December 31, 1997, and incorporated herein by reference.
10.24 Executive Long-Term Performance Equity Plan, effective as
of January 1, 1998, filed as Exhibit 10.1 to the Form 10-Q for
the quarter ended March 31, 1998, and incorporated herein by
reference.
10.25 First Amendment to Executive Long-Term Performance Equity
Plan, dated as of November 17, 1998.*
10.26 Amended and Restated Employment Agreement of Monty Fu,
dated January 1, 1997, and amended and restated as of December
31, 1997, filed as Exhibit 10.2 to the Form 10-Q for the quarter
ended March 31, 1998, and incorporated herein by reference.
10.27 Amended and Restated Employment Agreement of Robert G.
Funari, dated January 1, 1997, and amended and restated as of
December 31, 1997, filed as Exhibit 10.3 to the Form 10-Q for the
quarter ended March 31, 1998, and incorporated herein by
reference.*
10.28 1998 Senior Management Stock Purchase Plan, effective as
of June 16, 1998, filed as Exhibit 10.1 to the Form 10-Q for the
quarter ended June 30, 1998, and incorporated herein by
reference.*
10.29 Universal Performance Equity Participation Plan,
effective as of June 16, 1998, filed as Exhibit 10.2 to the Form
10-Q for the quarter ended June 30, 1998, and incorporated herein
by reference.*
10.30 New Employee Stock Option Plan, dated as of June 1, 1998,
filed as Exhibit 10.1 to the Form 10-Q for the quarter ended
September 30, 1998, and incorporated herein by reference.*
10.31 Form of Stock Option Agreement under the New Employee
Stock Option Plan as entered into between the Company and certain
employees.*
11. Statement Re: Computation of Per Share Earnings
Computation can be clearly determined from the material
contained in the Company's Annual Report to Stockholders for year
ended December 31, 1998.
13. Annual Report to Security Holders
Syncor International Corporation Annual Report to
Stockholders for the year ended December 31, 1998, except for
specific information in such Annual Report expressly incorporated
herein by reference, is furnished for the information of the
Commission and is not to be deemed "filed" as part hereof.
<TABLE>
<CAPTION>
21. Subsidiaries of the Registrant
<S> <C>
Name of Subsidiary State or Country of Organization
Syncor Management Corporation Delaware
Syncor Midland, Inc. Texas
Syncor Pharmaceuticals, Inc. Delaware
Comprehensive Medical Imaging, Inc. Delaware
Comprehensive Diagnostic Imaging, Inc.** Delaware
Medical Diagnostic Leasing, Inc.** Delaware
Syncor Diagnostics, LLC** California
TME, Inc.** Delaware
Beijing Syncor Medicine Corporation, Ltd. People's Republic of China
Pharmatopes (Proprietary) Limited*** South Africa
Shanghai Syncor Medicine Corporation, Ltd. People's Republic of China
Syncor de Mexico, S.A. de C.V.*** Mexico
Syncor de Puerto Rico, Inc.*** Puerto Rico
Syncor Hong Kong Limited*** Hong Kong
Syncor International (Thailand) Co., Ltd. Thailand
Syncor Korea, Inc.*** South Korea
Syncor New Zealand Limited*** New Zealand
Syncor Pharmacies Australia Pty. Ltd.*** Australia
Syncor Overseas Ltd. British Virgin Islands
Syncor Philippines, Inc.*** Philippines
Syncor Taiwan, Inc.*** Taiwan
Syncor Radiofarmacos, S.L. *** Spain
Syncor de Colombia, S.A. *** Colombia
Syncor Italy, S.R.L. *** Italy
Sichuan Syncor Medicine Corporation, Ltd. *** People's Republic of China
Alva Nuclear S.A. de C.V. *** Mexico
Alsyn Corporativos S.A. de C.V. *** Mexico
</TABLE>
23. Consent of KPMG LLP
27. Financial Data Schedule
_______________________________
* Management contracts or compensatory plan
** Subsidiaries of Comprehensive Medical Imaging, Inc.
*** Subsidiaries of Syncor Overseas Ltd.
<PAGE>
Exhibit 10.25
FIRST AMENDMENT TO
EXECUTIVE LONG-TERM PERFORMANCE EQUITY PLAN
This First Amendment to Executive Long-Term Performance Equity
Plan, dated as of November 17, 1998 (this "Amendment"), hereby
amends that certain Executive Long-Term Performance Equity Plan,
dated as of January 1, 1998 (the "Plan"), for Syncor
International Corporation, a Delaware corporation (the
"Company"). Initially capitalized terms used but not defined
herein shall have the same meaning thereto as set forth in the
Plan.
1. In determining the number of shares of Allocated Stock to
be awarded to a Participant, the dollar value of the Allocated
Stock award will be divided by $20, $25, $34 or $43, as the case
may be.
2. For purposes of determining the total shareholder return
(the "TSR") measure, the S&P Health Care Composite Index shall be
used for the first stock price target, and the S&P Small Cap
Health Care Index shall be used for each of the second, third
and fourth stock price targets.
3. The TSR measure will be comprised of a ratio of (i) the
Company's stock price growth during the 12-month period ending on
the date a stock price target is attained (i.e., on the tenth day
in which the closing price is at or above the stock price
target), to (ii) the growth of the applicable S&P health care
index during the corresponding period. If a stock price target
is attained on or before December 31, 1998, the comparison period
will commence on January 1, 1998 and end of the date the stock
price target is attained.
4. If price targets are overachieved relative to the
applicable S&P Health Care Index, the Option component of the
Award for overachievement (the part over target) will be paid in
cash, and the Allocated Stock component for overachievement may
be received in cash or in the Company's stock, at the discretion
of the Participant.
5. This Amendment is effective as of the date first set forth
above. Except as amended hereunder, all other terms and
conditions of the Plan shall remain in full force and effect.
<PAGE>
Exhibit 10.31
FORM OF
NEW EMPLOYEE STOCK OPTION PLAN
AWARD AGREEMENT
Name of Participant:
Address of Participant:
Social Security Number:
Number of Shares:
Exercise Price Per Share:
Award Date:
Expiration Date:
WHEREAS, pursuant to the Corporation's New Employee Stock Option
Plan (the "Plan"), the Participant has been granted a Non-
Qualified Stock Option (the "Option" or "Award") to purchase
shares of Common Stock of the Corporation upon the terms and
conditions hereinafter set forth;
NOW, THEREFORE, the Participant and the Corporation agree as
follows:
1. Grant of Option. The Corporation has granted to the
Participant as a matter of separate inducement and agreement in
connection with his or her employment, and not in lieu of any
salary or other compensation for his or her services, the right
and option to purchase, in accordance with the Plan and on the
terms and conditions of the Plan and those hereinafter set forth,
all or any part of the number of shares of Common Stock stated
above (the "Common Stock") at the price stated above (the
"Price"), exercisable from time to time subject to the provisions
of this Award Agreement prior to the close of business on the
Expiration Date stated above.
2. Exercisability of Option. Except as otherwise provided in
the Plan or this Award Agreement, the Option shall become
exercisable from time to time as follows: (i) 25% of the Common
Stock shall become purchasable twelve months after the Award
Date; (ii) an additional 25% of the Common Stock shall become
purchasable twenty-four months after the Award Date; (iii) an
additional 25% of the Common Stock shall become purchasable
thirty-six months after the Award Date; and (iv) an additional
25% of the Common Stock shall become purchasable forty-eight
months after the Award Date; provided, however, that the Option
may not be exercised as to less than 10 shares at any one time
unless the number of shares purchased is the total number at the
time available for purchase under an installment of the Option.
If the Participant does not, in any given installment period,
purchase all of the shares which he or she is entitled to
purchase in such installment period, the Participant's right to
purchase any shares not so purchased shall continue until the
Expiration Date, unless theretofore terminated in accordance with
the provisions hereof and of the Plan. The Option may be
exercised only as to whole shares.
3. Method of Exercise and Payment. Each exercise of the
Option shall be by means of written notice of exercise duly
delivered to the Corporation, specifying the number of whole
shares with respect to which the Option is being exercised,
together with any written statements required pursuant to Section
10 below and payment of the Price made in accordance with Section
2.2 of the Plan.
4. Not a Contract for Employment. Nothing contained in this
Award Agreement or in the Plan shall confer upon the Participant
any right to continue in the employ of the Corporation or
constitute any contract or agreement of employment. The
Participant acknowledges that the Corporation has the right to
terminate the Participant at will. Nothing contained in this
Award Agreement or in the Plan shall interfere in any way with
the right of the Corporation to (a) terminate the employment of
the Participant at any time for any reason whatsoever, with or
without cause, or (b) reduce the compensation received by the
Participant from the rate in existence on the Award Date.
5. Effect of Termination of Employment. The Option and all
other rights hereunder, to the extent such rights shall not have
been exercised prior thereto, shall terminate and become null and
void on the date the Participant ceases to be employed by the
Corporation; provided, however, that the Participant may, to the
extent the Option shall have become exercisable prior to such
date, exercise the Option at any time within (1) up to three
months after termination of employment other than termination for
Retirement, Total Disability, death or through discharge for
cause; (2) up to twelve months after such termination if such
termination occurs by reason of Retirement or Total Disability;
or (3) up to twelve months after the Participant's death, if the
Participant dies while in the employ of the Corporation or during
the period referred to in clause (2) above. During the period
after death, the Option may, to the extent exercisable on the
date of death (or earlier termination), be exercised by the
person or persons to whom the Participant's rights under the Plan
and this Award Agreement shall pass by will or by the applicable
laws of descent and distribution. Unless sooner terminated
pursuant to the Plan, the Option shall expire at the end of the
applicable period specified in clauses (1), (2) or (3) above, to
the extent not exercised within that period.
6. Non-Assignability of Option. The Option shall not be
subject to sale, transfer, pledge, assignment or alienation other
than by will or the laws of descent and distribution regardless
of any community property or other interest therein of the
Participant's spouse or such spouse's successor in interest. In
the event that the spouse of the Participant shall have acquired
a community property interest in the Option, the Participant, or
such transferees, may exercise it on behalf of the spouse of the
Participant or such spouse's successor in interest.
7. Adjustments Upon Specified Changes. As set forth in
Section 6.2 of the Plan, upon the occurrence of specified events
relating to the Corporation's stock, adjustments will be made in
the number and kind of shares that may be issuable under, or in
the consideration payable with respect to, an Award.
8. Acceleration. Upon the occurrence of an Event as defined
in the Plan, including a Change of Control, the Award shall
become immediately exercisable to the full extent theretofore not
exercisable unless prior to an Event the Board determines
otherwise; subject, however, to compliance with applicable
regulatory requirements, including without limitation Rule 16b-3
promulgated by the Securities and Exchange Commission pursuant to
the Securities Exchange Act of 1934, as amended (the "Exchange
Act").
9. Participant Not a Shareholder. Neither the Participant
nor any other person entitled to exercise the Option shall have
any of the rights or privileges of a shareholder of the
Corporation as to any shares of Common Stock for which stock
certificates have not been actually issued and delivered to him
or her. No adjustment will be made for dividends or other rights
for which the record date is prior to the date on which such
stock certificate or certificates are issued even if such record
date is subsequent to the date upon which notice of exercise was
delivered and the tender of payment was accepted.
10. Application of Securities Laws.
(a) No shares of Common Stock may be purchased pursuant
to the Option unless and until any then applicable requirements
of federal and state securities laws and regulations, and any
exchanges upon which the Common Stock may be listed, shall have
been fully satisfied. The Participant represents, agrees and
certifies that:
(i) If the Participant exercises the Option in whole
or in part at a time when there is not in effect under the
Securities Act of 1933, as amended (the "Securities Act"), a
registration statement relating to the Common Stock issuable upon
exercise and available for delivery to him or her a prospectus
meeting the requirements of Section 10 of the Securities Act
("Prospectus"), the Participant will acquire the Common Stock
issuable upon such exercise for the purpose of investment and not
with a view to resale or distribution and that, as a condition to
each such exercise, he or she will furnish to the Corporation a
written statement to such effect, satisfactory in form and
substance to the Corporation; and
(ii) If and when the Participant proposes to publicly
offer or sell the Common Stock issued to him or her upon exercise
of the Option, the Participant will notify the Corporation prior
to any such offering or sale and will abide by the opinion of
counsel to the Corporation as to whether and under what
conditions and circumstances, if any, he or she may offer and
sell such shares, but such procedure need not be followed if a
Prospectus was delivered to the Participant with the shares of
Common Stock and the Common Stock was and is listed on a national
securities exchange or traded as a National Market System
security through the facilities of NASDAQ.
(b) The Participant understands that the certificate or
certificates representing the Common Stock acquired pursuant to
the Option may bear a legend referring to the foregoing matters
and any limitations under the Securities Act and state securities
laws with respect to the transfer of such Common Stock, and the
Corporation may impose stop transfer instructions to implement
such limitations, if applicable. Any person or persons entitled
to exercise the Option under the provisions of Section 5 above
shall be bound by and obligated under the provisions of this
Section 10 to the same extent as is the Participant.
(c) The Board of Directors of the Corporation may impose
such conditions on an Award or on its exercise or acceleration or
on the payment of any withholding obligation (including without
limitation restricting the time of exercise to specified periods)
as may be required to satisfy applicable regulatory requirements,
including, without limitation, Rule 16b-3 (or any successor rule)
promulgated by the Commission pursuant to the Exchange Act.
11. Notices. Any notice to be given to the Corporation under
the terms of the Award Agreement or pursuant to the Plan shall be
in writing and addressed to the Secretary of the Corporation at
its principal office and any notice to be given to the
Participant shall be addressed to him or her at the address
stated above, or at such other address as either party may
hereafter designate in writing to the other party. Any such
notice shall be deemed to have been duly given when enclosed in a
properly sealed envelope addressed as aforesaid, registered or
certified, and deposited (postage and registry or certification
fee prepaid) in a post office or branch post office regularly
maintained by the United States Government.
12. Effect of Award Agreement. The Award Agreement shall be
assumed by, be binding upon and inure to the benefit of any
successor or successors of the Corporation to the extent provided
in Section 6.2(b) of the Plan.
13. Tax Withholding. The provisions of Section 6.6 of the
Plan are hereby incorporated and shall govern any withholding
that the Corporation or Subsidiary employing the Participant is
required to make with respect to an exercise of the Option, as
well as the Corporation's right to condition a transfer of Common
Stock upon compliance with the applicable withholding
requirements of federal, state and local authorities.
14. Terms of Plan Govern. The Award and this Award Agreement
are subject to, and the Corporation and the Participant agree to
be bound by, all of the terms and conditions of the Plan.
Capitalized terms used in this Award Agreement have the meanings
defined in the Plan. The Participant acknowledges receipt of a
copy of the Plan. The rights of the Participant are subject to
limitations, adjustments, modifications, suspension and
termination in certain circumstances and upon the occurrence of
certain conditions as set forth in the Plan.
15. Law Applicable to Construction; Currency. The
interpretation, performance and enforcement of the Award and this
Award Agreement shall be governed by the laws of the State of
Delaware. All currencies expressed are in U.S. Dollars.
16. Notice of Disposition. The Participant agrees to notify
the Corporation of any sale or other disposition of any shares of
Common Stock received upon exercise of the Option if such sale or
disposition occurs within two years after the Award Date or
within one year after the date of exercise of the Option.<PAGE>
IN WITNESS WHEREOF, the Corporation has caused this Award
Agreement to be executed on its behalf by a duly authorized
officer and the Participant has hereunto set his or her hand as
of the Award Date.
CORPORATION: PARTICIPANT:
SYNCOR INTERNATIONAL CORPORATION,
a Delaware corporation
By:_____________________________ ___________________________
Robert G. Funari
President and Chief Executive
Officer
Date:____________________________ Date:______________________
CONSENT OF SPOUSE
I join with my spouse, the Participant herein named, in executing
the foregoing Non-Qualified Stock Option Award Agreement and
agree to be bound by all of the terms and provisions thereof and
of the Plan.
__________________________________
Signature of Participant's Spouse
Exhibit 13
SYNCOR 1998 ANNUAL REPORT
<PAGE>
Outside Front Cover:
[A photo of a Syncor Driver carrying a delivery case in to the Emergency
Department of a hospital. A syncor prescription label is on the bottom
left side]
SYNCOR INTERNATIONAL CORPORATION 1998 ANNUAL REPORT
Inside Front Cover:
[Corporate Profile]
CORPORATE PROFILE
Syncor International Corporation is the world's leading provider of
radiopharmaceuticals and comprehensive nuclear pharmacy services. Through
Comprehensive Medical Imaging, Inc., a wholly owned subsidiary, Syncor is
also one of the nation's leading providers of medical imaging services.
Syncor pioneered the outsourcing of radiopharmacy services in 1974.
Through its core specialized pharmacy services business, Syncor compounds
and dispenses radiopharmaceuticals for diagnostic and therapeutic use by
nuclear medicine departments in hospitals and outpatient clinics. Syncor
distributes these time-critical products - in patient-specific unit-dose
and multidose form - through an integrated network of strategically located
pharmacies: 120 domestic and 14 international. This network, which serves
more than 7,000 customers, also provides nuclear medicine management and
information services.
Syncor entered the $60 billion medical imaging services market in 1997
and now, through Comprehensive Medical Imaging, owns or operates 37 medical
imaging centers in selected metropolitan areas in 11 states and Puerto
Rico. In 1998, Syncor also began expanding its medical imaging business
into international markets through Syncor Overseas Ltd., the subsidiary
responsible for the Company's rapidly growing overseas operations.
Another subsidiary, Syncor Pharmaceuticals, Inc., manufactures Iodine-
123 capsules, which are used to diagnose thyroid disorders.
<TABLE>
<CAPTION>
FINANCIAL HIGHLIGHTS
Year Ended Year Ended Year Ended
December 31, December 31, December 31,
(In thousands, except per share data) 1998 1997 1996
____________________________________________________________________________________________________
<S> <C> <C> <C>
Net sales $449,023 $380,563 $366,447
Net income - continuing operations $ 13,931 $ 10,032 $ 6,900
Net income per basic share - continuing operations $ 1.30 $ 1.00 $ 0.66
Net income per diluted share - continuing operations $ 1.23 $ 0.98 $ 0.65
Cash, cash equivalents and marketable securities $ 19,722 $ 29,301 $ 27,711
Cash generated by operations $ 33,604 $ 22,529 $ 16,070
</TABLE>
[There are (4) Bar Charts drawn as follows:]
Net Sales 1994-1998
Net Income - Continuing Operations 1994-1998
Earnings Per Diluted Share, Continuing Operations 1994-1998
Stock Price (high/low/close) 1994-1998
SYNCOR'S MISSION
Syncor will be the undisputed worldwide leader in providing comprehensive
imaging, specialized pharmacy and management services to the healthcare
community.
SYNCOR'S STRATEGY FOR GROWTH
Our growth strategy consists of two objectives. The first calls for the
continued expansion and strengthening of our position as the world's
leading provider of radiopharmacy services. The second objective is to
achieve leadership in the medical imaging field through selective
investments and acquisitions and the development of innovative business
approaches to imaging services that will meet the changing needs of
physicians and patients.
SYNCOR'S TRADITION OF LEADERSHIP
Syncor is the recognized service leader in the radiopharmaceuticals
business. We attained this position by pioneering the outsourcing of
radiopharmaceutical compounding services. We maintain this position through
innovations that add value.
Examples:
1991 Introduced the Unit Dose Manager(TM), the industry's first integrated
nuclear medicine department information system for the management of
unit-dose radiopharmaceuticals.
1992 Established the first national network of radiopharmaceutical
information support specialists.
1994 Became the preferred distributor of DuPont Merck's Cardiolite(R),
which has since become the industry's "gold standard"
radiopharmaceutical for stress testing.
1994 Introduced SECURE(TM), a unique delivery system that reduces
biohazards associated with the handling of radiopharmaceutical
injection devices.
1995 Established the only in-house Authorized Nuclear Pharmacist Training
Program, recognized by the Nuclear Regulatory Commission (NRC) and
accredited by the American Council on Pharmacy Education.
1996 Introduced NUCLink(TM) software, which enables two-way communication
between Syncor radiopharmacies and customers for placing orders and
determining their status.
1997 Introduced the Service Difference Guarantee(SM), the industry's first
written guarantee that customer service expectations would be met or
exceeded.
1997 Introduced SYNtrac(TM), the industry's first Windows-based software
system for monitoring and managing nuclear medicine department
functions.
1998 Introduced Piglet(TM), Piglet 2(TM), and PETPig(TM), the industry's
first tungsten product delivery containers for optimal radiation
shielding with minimal weight.
1998 Developed the first and only Nuclear Pharmacy Technician training
program.
SYNCOR'S EXTRAORDINARY YEAR AT A GLANCE
January Made a commitment to enhance stockholder value by doubling
earnings per share over a four-year period.
January Signed first nationwide contract with Kaiser Foundation Health
Plan, America's largest not-for-profit HMO, for radiopharmaceutical
services.
January Announced the acquisition of three medical imaging businesses:
National Diagnostic Services, Inc., International Magnetic Imaging,
Inc., and TME, Inc.
March Achieved over $102 million in first quarter sales - the highest
quarterly sales volume in Syncor's 24-year history.
April Articulated a new strategy for international business growth via
expansion of medical imaging services and strategic overseas
acquisitions.
May Consolidated the medical imaging businesses into Comprehensive Medical
Imaging, Inc., a wholly owned subsidiary.
June Received stockholder approval of new senior management stock purchase
and universal employee stock option plans that better align the
interests of stockholders, management and employees.
June Became the exclusive distributor of positron emission tomography (PET)
radiopharmaceuticals produced by one of New England's largest
hospitals.
July Reported record earnings from continuing operations and a 64 percent
increase in operating income for the second quarter as well as a
second consecutive quarter of record sales in excess of $100 million.
August Entered technology licensing and consulting agreements with the
government of Israel for Syncor's first licensee-operated
radiopharmacy.
September Increased coverage of the Washington, D.C. area with the
acquisition of a new imaging center in Fairfax, Virginia.
October Announced a 119 percent operating income increase for the third
quarter and an 86 percent increase for the nine months ended September
30.
December Established Syncor's first free-standing overseas medical imaging
facility in Auckland, New Zealand.
December Completed construction in Bogota, Colombia, of Syncor's first
South American radiopharmacy.
December Celebrated highest Syncor stock price of the year: $27.25 per
share - up 69 percent from $16.13 in December 1997.
[A photo of John Harloe and James S. McClure]
"When a company's plan for improving profitability includes incentives that
enable employees to benefit financially, good things happen - as, in fact,
they have at Syncor. As soon as they made their stock options more
inclusive, operating margins improved substantially."
John Harloe and James S. McClure
Barrow Hanley McWhinney & Strauss
Dallas, Texas
Syncor's Institutional Stockholder
TO OUR SHAREHOLDERS
Syncor had an extraordinarily good year in 1998, and we have you to thank.
Last spring you approved a senior management stock purchase plan that more
closely aligns management performance with stockholder interest and a
universal employee stock option plan that creates innovative wealth-sharing
opportunities for our business partners. Combined with a management
performance plan that links the officers' bonuses to the attainment of
stock targets, these plans have generated outstanding results.
We began 1998 with Syncor's stock trading at $16 per share. By December,
Syncor's stock was trading at $27 per share, already exceeding our 1999
target of $25 per share and forging toward our $34 per share target for the
year 2000.
This impressive rise in market valuation reflects an equally strong
improvement in the Company's financial performance. We started 1998 with a
commitment to double earnings per share over a four-year period. In the
first year of this effort, per-share earnings from continuing operations
increased by 26 percent - from $.98 per diluted share in 1997 to $1.23 per
diluted share in 1998.
Much of this increase in Syncor's earnings is attributable to a
phenomenal improvement in the financial performance of our radiopharmacy
services. We are proud to report that this business - under the leadership
of Executive Vice President and Chief Operating Officer Brad Nutter -
increased net sales 9 percent over the prior year, while improving gross
margins and reducing operating expenses. This financial performance
resulted in a 23 percent increase in pre-tax operating income for 1998.
In the 1997 annual report, we also articulated a commitment to transform
Syncor from a $381 million single-business company to a $600 million
multibusiness enterprise by 2001. One year into this process, we are
pleased to report that 1998 sales reached a record $449 million with 8
percent of these revenues generated by our new medical imaging business. We
anticipate that Syncor's market value will continue to rise in step with
the Company's financial performance.
Ultimately, Syncor's financial performance and market valuation reflect
the value we provide to our customers. It is the Company's ongoing
tradition of innovating in order to add value to our services that has made
Syncor the undisputed leader in the radiopharmacy business. By applying the
same dedication to providing superior value to medical imaging, we intend
to make Comprehensive Medical Imaging, Inc. ("CMI"), the undisputed leader
in that field as well.
As for what constitutes added value, we recognize that only our
customers are in a position to judge the worth of Syncor's services. For
this reason, we invited several of our leading customers - as well as a
major institutional investor who has taken a significant position with
Syncor - to give us feedback on why they have chosen our company. We are
honored to feature their comments in these pages and hope that they will
give you a stronger sense of what Syncor has to offer.
Before closing, we would like to take this opportunity to welcome
Syncor's newest director and also the newest members of the Company's
senior management team. Ronald Williams, president of Blue Cross of
California, was elected to the Board of Directors in December 1998. David
Ward, formerly president of American Rehability Services, Inc., was named
president and chief executive officer of CMI in March 1999. Also, early
last year, Haig Bagerdjian, formerly Syncor's general counsel and senior
vice president of business development, became president of Syncor Overseas
Ltd. and executive vice president and chief legal officer for Syncor. His
successor as general counsel is John S. Baumann, who came to Syncor from
KPMG LLP and is also a corporate vice president.
On behalf of the Board of Directors, the corporate officers and Syncor's
more than 3,000 worldwide business partners, we thank you for your
continued support and confidence in us. We look forward in continuing to
create greater stockholder value through leadership in radiopharmacy and
medical imaging services through 1999 and beyond.
/s/ Monty Fu
_______________________________
Monty Fu, Chairman of the Board
/s/ Robert G. Funari
_______________________________
Robert G. Funari, President and Chief Executive Officer
March 31, 1999
[A photo of Syncor's Officers]
Standing (from left): Monty Fu, John S. Baumann, Brad Nutter, Haig S.
Bagerdjian, Jack L. Coffey
Seated (from left): Robert G. Funari, Sheila H. Coop, Michael E. Mikity
[There are 4 photos on Page 6]
Photo #1 Syncor pharmacist preparing a Nuclear Medicine dose in one of
Syncor's locations
Photo #2 nuclear medicine scan of the heart
Photo #3 nuclear medicine scan of the heart
Photo #4 Mr. Ken Roseman and the caption reads:
"Syncor works cooperatively, proactively and ethically with AmeriNet and
our more than 2,000 member hospitals. Syncor is an industry innovator.
Their safety devices and computer programs are very useful tools that
aren't available from anyone else. They've been doing a great job for us
since 1992."
Ken Roseman, Vice President, Program Development, AmeriNet, St. Louis,
Missouri
RADIOPHARMACY
Syncor leads in the nation's radiopharmacy services market for three
reasons. The first is the Company's operational excellence, which sets the
industry standard. Syncor consistently delivers the right
radiopharmaceutical doses to the right places at the right times. Our
reported dispensing error rate - .0000173 percent of the more than six
million doses we deliver annually - compares most favorably to the reported
retail pharmacy rate of 1 to 2 percent.
The second reason for Syncor's leadership has to do with the value-
adding innovations we continually develop and refine to enable our hospital
nuclear medicine department customers to better manage their operations and
comply with complex regulatory requirements. (Please see page 2 for a
summary of Syncor service "firsts").
Syncor's ability to create the right kinds of innovations and service
refinements stems from the breadth and depth of our customer relationships.
No other industry provider has Syncor's volume or frequency of customer
contact. More than 90 percent of our radiopharmacy employees have multiple
direct daily contacts with customers in 7,000 hospitals, clinics and
imaging centers every day.
This exceptional degree of direct daily contact has resulted in the
third reason for Syncor's leadership in radiopharmacy services: specialized
knowledge. The unrivaled closeness that we enjoy with customers not only
enables us to understand, anticipate and satisfy their needs but also
provides Syncor with comprehensive information on the actual use and
performance of the products we compound and deliver. Because we are the
nation's leading provider of radiopharmacy services - with approximately 52
percent market share and a pharmacy network that serves more than 93
percent of the communities where nuclear medical imaging services are
available - the information we gather is highly indicative of how
radiopharmaceuticals are used and how prescribing physicians perceive their
effectiveness and safety. As such, the value of this information to
manufacturers is also high, and Syncor is the only pharmacy services
provider that systematically offers manufacturers comprehensive data of
this type.
The Company's ability to bring so much valuable information back to
manufacturers as well as forward to customers is unique. Through the
refinement of its capabilities, Syncor is preparing to play a new type of
leadership role as the central information repository for the nuclear
medicine industry.
Meanwhile, Syncor plans to enhance its position as the radiopharmacy
services market leader by strengthening its national nuclear pharmacy
network, augmenting and further differentiating the Company's services, and
expanding product offerings by diversifying the Syncor Pharmaceuticals,
Inc. product line and developing new relationships with other
manufacturers.
[There are 5 photos on page 8]
Photo #1 CMI Technician screening images of a patient whose head is
being scanned in one of Syncor's CMI locations.
Photo #2 Dr. J. Bruce Jacobs and the caption reads:
"My partnering experience with Comprehensive Medical Imaging has been very
positive. I sold them the technical side of my practice a year ago. I
retain operational control. The benefits are many: More capital for new
equipment. More negotiating power. Improved vendor and employee
relations. Expanded marketing contacts. Access to a nationwide
information network."
J. Bruce Jacobs, MD
Desert CT/MRI
Palm Springs and Rancho Mirage, California
Photo #3 Maria Greenwald and the caption reads:
"Dr. Jacobs and Desert CT/MRI provide first rate service to me and my
patients. They are invariably accommodating with rapid, responsive
reports. The quality of their radiographic technique and interpretation is
uniformly highly regarded throughout the Coachella Valley."
Maria Greenwald, M.D., F.A.C.R.
Rancho Mirage, California
Photo #4 MRI image of the brain
Photo #5 MRI image of the skull
MEDICAL IMAGING
Syncor's newest subsidiary, Comprehensive Medical Imaging, Inc. ("CMI"),
contributed $37 million to the Company's 1998 revenues. We believe that
this business will experience rapid profitable growth over the next several
years. CMI's long-term objective is to become the leading provider of high-
value, comprehensive medical imaging, radiology, and information management
services to healthcare providers. CMI plans to earn its leadership position
by consistently providing high-quality, cost-effective service that results
in increased physician and patient satisfaction and improved patient
outcomes.
Since its formation in May 1998, CMI has focused on integrating its
operations into an overall strategy for attaining its long-term objective.
This strategy consists of two parts. The first concentrates on enhancing
the current free-standing imaging center business and the second on
developing a future business in hospital radiology outsourcing and medical
imaging shared-service networks.
Underlying these strategies are a number of basic operating principles,
the first of which is the recognition that hospitals are our most important
customers. Hospitals account for more than 75 percent of all spending on
medical imaging products and services. They also represent more than 80
percent of Syncor's current revenues, which means that CMI has a unique
opportunity to differentiate itself from other imaging service providers by
collaborating with these institutions to create win-win relationships.
Steps toward enhancing CMI's current business include making selective
investments and acquisitions in markets where CMI can achieve market
leadership; developing a new model for doing business with radiologists
that aligns their interests - and the Company's - with those of payers and
providers; building or acquiring outstanding competency in the areas of
billing and collections; and strengthening the sales and marketing
organization in order to communicate the service and value difference that
CMI provides.
The lead strategy for developing the Company's future business consists
of building a superior knowledge base in the areas of revenue flows,
activity-based costing, and best demonstrated medical imaging practices in
order to identify opportunities for improvement in both the outpatient and
inpatient medical imaging markets. The next component calls for identifying
intermediate steps that can move CMI toward its future businesses. Examples
may include managing hospital nuclear medicine departments and hospital-
owned off-site medical imaging centers, as well as exploring radiology
outsourcing arrangements with existing Syncor hospital customers. Finally,
CMI will make acquisitions as needed to bring in the skills and provide the
market presence required for successful growth in these new business areas.
[A U.S. Map showing U.S. Medical Imaging Locations]
[There are 5 photos on page 10]
Photo #1 showing a technologist getting a patient prepared to be scanned.
Photo #2 Dr. Barry Elison and the caption reads:
"Our practices have been Syncor customers since the company opened its
first Australian radiopharmacy in 1997. I have been delighted with our
association. By utilizing Syncor products and services, we have derived
enormous benefits - especially in patient-scheduling flexibility and the
convenience this offers our technologist staff."
Barry Elison, MD FRACP
Partner, Western Nuclear Medicine and
Wollongong Nuclear Medicine
Sydney, Australia
Photo #3 MRI image
Photo #4 MRI image
Photo #5 MRI image
INTERNATIONAL
Syncor's international subsidiary, Syncor Overseas Ltd., increased its
revenues in 1998 by 52 percent and is aiming at annual sales of $75 million
in 2001. A new business strategy, introduced early in 1998, is driving this
accelerated growth. The new strategy differs from the previous business
approach in two respects.
Traditionally, Syncor Overseas expanded geographically by entering new
markets to establish radiopharmacies. Because "greenfielding" in this
manner incurs start-up losses for a relatively long period, the Company is
now beginning to penetrate new markets through related businesses that
generate profits more quickly, such as medical imaging, distribution of
nuclear medical equipment and supplies, and management of nuclear medicine
departments. For example, Syncor Overseas recently opened its first free-
standing outpatient medical imaging facility in Auckland, New Zealand.
While Auckland could not have supported a full-scale, stand-alone nuclear
pharmacy operation at this time, the new imaging center - which also
includes a small radiopharmacy - gives the local medical community the best
of both worlds.
The second difference in strategy involves acquisitions. For the first
time in its 13-year history, Syncor Overseas will be entering and expanding
its presence in several promising markets by acquiring existing medical
imaging businesses. The Company expects international acquisitions to
account for a substantial portion of Syncor Overseas' revenues in 1999.
Syncor Overseas will continue to expand in more traditional ways as
well. The Company recently opened its first South American radiopharmacy in
Bogota, Colombia, and its first European radiopharmacy is scheduled to open
later this year in Santiago, Spain.
The Company established its first overseas nuclear pharmacy in 1987 in
Taiwan. Syncor now operates three radiopharmacies in that country and is
Taiwan's leading radiopharmacy services provider. In this advanced Asian
healthcare market, Syncor also manages the in-house nuclear medicine
departments of three major hospitals.
Syncor Overseas also operates a growing catalog sales business featuring
medical imaging supplies and equipment and has begun to franchise the
Company's management expertise as well as its proprietary management
information and product delivery systems. During 1998, Syncor entered into
licensing agreements with the government of Israel for the establishment of
a pilot franchised nuclear pharmacy in Tel Aviv.
Syncor intends to achieve leadership in world markets with the same
strengths that have made the Company the undisputed leader in the U.S. What
Syncor brings to the international marketplace - in addition to
demonstrated operational excellence and a proven commitment to customer
service - is knowledge of medical imaging and radiopharmacy operations as
businesses. Because the need to control healthcare costs is universal,
Syncor's formula for creating value for customers, partners, and payers has
enormous potential for successful application worldwide.
[A World Map showing International Pharmacy Service Centers]
<TABLE>
<CAPTION>
FINANCIAL INFORMATION
SYNCOR INTERNATIONAL CORPORATION AND SUBSIDIARIES
TABLE OF CONTENTS
PAGE
Selected Financial Data....................................................13
Management's Discussion and Analysis Results of Operations.................14
Consolidated Balance Sheet.................................................19
Consolidated Statements of Income..........................................20
Consolidated Statements of Stockholders' Equity and Comprehensive Income...21
Consolidated Statements of Cash Flows......................................22
Notes to Consolidated Financial Statements.................................23
Report of the Independent Auditors.........................................39
Management's Report........................................................39
Stockholder Information.....................................Inside Back Cover
=============================================================================
SELECTED FINANCIAL DATA
TWELVE MONTHS ENDED DECEMBER 31,
(IN THOUSANDS EXCEPT PER SHARE DATA) 1998 1997 1996 1995 1994
______________________________________________________________________________________________________
<S> <C> <C> <C> <C> <C>
Net sales $449,023 $380,563 $366,447 $331,435 $319,193
Gross profit 131,950 90,165 80,193 73,626 $ 66,186
Income (loss):
Continuing operations 13,931 10,032 6,900 4,984 1,390
Discontinued operations, net of taxes - 1,063 (2,264) (315) (177)
Net income 13,931 11,095 4,636 4,669 1,213
===========================================================
Earnings per basic share:
Continuing operations 1.30 1.00 0.66 0.48 0.13
Discontinued operations, net of taxes - 0.11 (0.22) (0.03) (0.02)
Net income $ 1.30 $ 1.11 $ .44 $ .45 $ .11
============================================================
Earnings per diluted share:
Continuing operations 1.23 0.98 0.65 0.48 0.13
Discontinued operations, net of taxes - 0.10 (0.21) (0.03) (0.02)
Net income $ 1.23 $ 1.08 $ 0.44 $ 0.45 $ 0.11
============================================================
Cash, cash equivalents and
marketable securities $ 19,722 $ 29,301 $ 27,711 $ 26,559 $ 19,201
Working capital $ 44,024 $ 34,685 $ 35,515 $ 34,286 $ 26,616
Total assets $256,567 $164,563 $145,563 $133,680 $128,684
Long-term debt $ 70,322 $ 17,332 $ 7,595 $ 5,200 $ 5,154
Stockholders' equity $111,373 $ 87,367 $ 78,532 $ 78,262 $ 73,850
Weighted average shares outstanding:
Basic 10,726 9,998 10,424 10,341 10,507
Diluted 11,339 10,282 10,629 10,481 10,507
Current ratio 1.59 1.60 1.62 1.69 1.54
=============================================================
Number of domestic radiopharmacies 120 119 121 118 117
Days sales outstanding (excluding CMI) 54 51 50 55 55
=============================================================
</TABLE>
Management's Discussion and Analysis
Results of Operations Calendar Year 1998 and 1997
NET SALES
Consolidated net sales in 1998 totaled $449 million, an increase of 18
percent or $69 million over the 1997 results. Syncor International
Corporation's 1998 sales were positively affected by a number of factors,
among which were strong growth in the cardiology-imaging market and the
addition of the Medical Imaging business.
PHARMACY SERVICES BUSINESS
Pharmacy Services sales in 1998 were $412 million, an increase of 8
percent or $31 million over the 1997 results. Growth in this market is
currently estimated to be expanding at an annual rate of approximately 16
percent. Although the Company primarily supplies products for diagnostic
purposes in the fields of oncology, cardiology and neurology, it is the
strong growth in the cardiology marketplace that continues to drive sales.
The principal cardiology-imaging agent continues to be DuPont's cardiology
product, Cardiolite(TM), for which Syncor has preferred distribution
rights. A competing radiopharmaceutical manufacturer/distributor is
currently marketing a rival product to Cardiolite(TM). This competing
product continues to gain some market share in this rapidly growing market.
During 1998, several generic cardiology products (also distributed by the
Company and available through a variety of sources) continued to experience
volume declines as customers switched to the newer available imaging
agents. In August of 1998, the Company instituted a price increase on
Cardiolite(TM) and certain other products. Pricing for the remaining
cardiology agents remained relatively flat during 1998. When all of the
above factors are combined, the Company showed an annual gain in overall
cardiology sales of approximately 14 percent. Cardiology sales constituted
approximately 65 percent of the Company's 1998 sales. Syncor expects the
trends discussed above to continue; however, the Company also expects the
growth in the cardiology marketplace (particularly due to Cardiolite(TM))
to offset the negative factors.
The Company recently announced the loss of a contract to sell
radiopharmaceuticals to a Group Purchasing Organization. In the
announcement, the Company indicated the annual loss of sales volume would
be limited to approximately $10 to $15 million although the contract award
was for a significantly larger amount. The Company also believes that the
effect on earnings as a result of the loss of this contract will not be
material. This belief is based on the Company's experience with the loss of
a similar contract in a competitive bidding process approximately two years
ago. The Company believes the strong customer loyalty and resulting
business retention, despite a contractual loss, are the results of its
ability to provide superior service to its customers. The outlook for 1999
continues to remain positive. Despite the negative factors discussed above,
Syncor continues to expect net revenue gains from it radiopharmacy
business.
MEDICAL IMAGING BUSINESS
In 1997, the Company entered into the medical diagnostic imaging business
with the planned start-up of ten "Open MRI" centers as part of a joint
venture. As of December 31, 1998, seven of those ten centers were
operational. During 1998, the Company acquired three medical imaging
companies for approximately $47 million and the assumption of $34 million
in various liabilities. These acquisitions were all completed on or about
the end of the first quarter of 1998 and now operate, along with the Open
MRI business, under a newly formed subsidiary, Comprehensive Medical
Imaging, Inc. ("CMI"). Revenues for 1998 amounted to approximately $37
million and are included in the consolidated operating results of the
Company. Revenues for the Medical Imaging business in 1997 were negligible.
GROSS MARGIN
Syncor's gross margin increased in 1998 to $132 million, an increase of
46 percent when compared to 1997. As a percentage of net sales, gross
profit increased to 30 percent, compared to 24 percent in 1997. Gross
profit was affected by a number of issues, including mix shift, price
increases, a reduction in certain material acquisition costs and the
addition of the Medical Imaging business, which generates substantially
higher gross margins when compared to the Pharmacy Services business.
PHARMACY SERVICES BUSINESS
The Company continues to experience a shift in its sales mix as a result
of growth in the cardiology sector. Generally, servicing this sector
produces higher margins than other sectors. In addition, the Company
received incentives from a manufacturer for achieving certain sales volume
levels plus some price decreases on selected products. In August 1998, the
Company instituted a price increase, primarily on cardiology products. This
price increase was phased in to correspond with contract renewal dates and
other issues. Labor costs in 1998 were targeted for increased focus in
order to ensure optimal utilization of resources and the attainment of
certain efficiencies. As a result, labor costs for 1998 in the Pharmacy
Services business were maintained at approximately the 1997 levels. Labor
costs will continue to be targeted in 1999 for the express purpose of
increasing efficiencies and maximizing utilization.
MEDICAL IMAGING BUSINESS
The Medical Imaging business had gross margins which amounted to $28
million or 74% of net sales for 1998, the first year of operations. During
1998, certain actions were taken to eliminate low-paying contracts and
strengthen CMI's radiology affiliations to provide better quality radiology
services and greater geographic coverage. The short-term impact of these
decisions reduced revenues and gross margins during the second and third
quarter of 1998 until new third-party payer contracts and radiology
agreements were established.
OPERATING, SELLING AND ADMINISTRATIVE COSTS
Operating, selling and administrative expenses increased $30 million in
1998 as compared to 1997, and as a percentage of 1998 net sales to 24
percent compared to 20 percent in 1997. Operating expenses increased
primarily as a result of the acquisition of the Medical Imaging business.
The Medical Imaging business acquisition and subsequent operations
accounted for approximately $25 million or 82 percent of this increase. The
Medical Imaging business typically has less cost of goods sold and a
greater proportion of indirect operating costs related to salaries,
equipment costs, billing fees and expenses, and building leases.
In addition, increases were due to including a full year of operation of
certain manufacturing facilities and the expansion of the international
radiopharmacy business. Costs associated with the conversion of the
Company's systems (year-2000 compliance), expansion of the information
technology infrastructure, and continued investment in re-engineering
certain critical business practices were also incurred. Programs that focus
on the long-term competitiveness of the Company continue to receive
funding.
Operating, selling and administrative expenses are expected to increase
from their current levels although not as dramatically. This expansion will
occur as the Medical Imaging business is expanded and has a full year of
operations, new systems are implemented as a result of our re-engineering
efforts, new field systems are designed, and expansion continues in the
international marketplace.
DEPRECIATION AND AMORTIZATION
Depreciation and amortization in 1998 increased to $15 million from $10
million in 1997. The majority of the increase is associated with the
purchase of the Medical Imaging business. Depreciation and amortization
expense for the Medical Imaging business amounted to $5 million, which
included approximately $1.5 million relating to amortization of goodwill.
In addition, the Company's depreciation expense also increased with
increased systems infrastructure.
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
Interest income earned on the Company's investment portfolio is affected
by changes in the general level of U.S. interest rates. The Company's
short-term borrowings effectively bear interest at variable rates and
therefore, changes in U.S. interest rate affect interest expense incurred
thereon. Changes in interest rates do not affect interest expense incurred
on the Company's long-term borrowings because they all bear interest at
fixed rates. The table below provides information about the Company's
financial debt instruments that are sensitive to changes in interest rates.
The table presents principal cash flows and related weighted-average
interest rates by expected maturity dates. The Company did not engage in
any interest rate swaps during this period. The fair value of these
instruments approximate the carrying value.
<TABLE>
<CAPTION>
DECEMBER 31, 1998 There-
(IN THOUSANDS) 1999 2000 2001 2002 2003 after Total
_________________________________________________________________________________________________
<S> <C> <C> <C> <C> <C> <C> <C>
Long-term debt
Fixed rate $ 6,912 $ 4,670 $ 3,541 $ 2,472 $ 926 $ 3,368 $21,889
Average interest rate 8.90% 8.73% 8.38% 7.76% 6.76% 6.21%
Variable rate $ 2,210 $ 2,385 $48,385 $ 4,575 0 0 $57,555
Average interest rate 6.81% 6.58% 0.00% 0.00%
</TABLE>
RESULTS OF OPERATIONS, CALENDAR YEARS 1997 AND 1996
NET SALES
Consolidated net sales in 1997 totaled $380 million, an increase of 4
percent or $14 million over the 1996 results. Syncor International
Corporation's 1997 sales were affected by a number of conflicting factors.
The expanding cardiology market place continues to drive sales growth.
Expansion in this market is comprised of several products and is currently
estimated at approximately 17 percent. The principal cardiology-imaging
agent continues to be DuPont's cardiology product Cardiolite(TM) for which
Syncor has preferred distribution rights. A competing radiopharmaceutical
manufacturer/distributor is currently marketing a rival product to
Cardiolite(TM). This new product was introduced late last year and also
continues to gain some market share, currently estimated at 12 percent of
the total profusion market. In addition to Cardiolite(TM), several generic
cardiology products (also distributed by the Company and available through
a variety of sources) continue to experience volume declines as customers
switch to the newer available imaging agents. Pricing for all cardiology
agents has been steady during the current year with the exception of one
product experiencing a significant decline. When all of the above factors
are combined, the Company shows an annual gain in overall cardiology sales
of approximately 8.2 percent. Cardiology sales currently constitute
approximately 65 percent of the Company's annual sales. Syncor expects the
trends discussed above to continue; however, the Company also expects the
growth in the cardiology marketplace (particularly due to Cardiolite(TM))
to offset the negative factors.
In 1997, Syncor announced the loss, through the process of competitive
bidding, of a contract to supply products to a large hospital-supplies
buying group. The annual revenues associated with this buying group are
estimated to be in the range of $60 to $65 million. The Company also stated
at that time that certain steps would be taken to minimize the impact of
losing this contract. During 1997, Syncor was successful in reducing the
potential loss associated with the lost contract to a total of
approximately $8 million, with estimated lost pretax profits at $1.6
million. The Company continues to implement steps to minimize the long-term
impact on revenues and profits from the lost contract.
GROSS MARGIN
Syncor's gross margin increased in 1997 to $90.2 million, an increase of
12.4 percent when compared to 1996. However, when viewed as a percentage of
net sales, gross profit increased to 23.7 percent, compared to 21.9 percent
in 1996. Gross profit was affected by a number of issues, chiefly a
reduction in certain material acquisition costs. During 1997, the Company
announced the re-negotiation of a contract for materials acquisition from
one of its principal suppliers. The contract contained certain volume
levels plus an increased period of time in which the Company would continue
to utilize the supplier on a sole-source basis. In exchange for these
commitments, the Company received favorable pricing on some of the generic
products distributed by the supplier. Many of these provisions expired in
December 1997; however, marketplace economics have dictated that these
pricing levels remain in effect in 1998. Offsetting these gains in material
costs were higher-than-expected labor costs in the core business. Increased
labor costs were being driven by shortages in key positions and market
economics that were not offset by price increases. In addition, Syncor
instituted a pilot program, which provided for incentive bonuses if certain
key business goals were reached. The Company believes that the program was
successful and will be expanding it beyond the original pilot group in
1998. Continued monitoring of labor costs in 1998 has been established in
order to ensure optimal utilization of resources. The goal will be to
contain labor costs at the 1997 level in the core business.
OPERATING, SELLING AND ADMINISTRATIVE COSTS
Operating, selling and administrative expenses increased $6.1 million in
1997 as compared to 1996, and as a percentage of 1997 net sales to 17.7
percent compared to 16.7 percent in 1996. Operating expenses increased for
a number of reasons, including the acquisition of certain manufacturing
facilities, the start-up and operation of the diagnostic imaging business,
the expansion of the international radiopharmacy business, and severance
costs associated with the reorganization of certain aspects of the core
business. Other expense increases were due to the conversion of the
Company's financial systems (year-2000 compliance), expansion of the
information technology infrastructure, continued investment in re-
engineering certain critical business practices, and programs that focus on
the long-term competitiveness of the Company.
DEPRECIATION AND AMORTIZATION
Depreciation and amortization in 1997 decreased to $9.9 million from
$10.4 million in 1996. The decrease is due to capitalized start-up costs,
consulting and non-compete agreements originating prior to 1996 and
becoming fully amortized during the year.
LIQUIDITY AND CAPITAL RESOURCES
The acquisition of the Medical Imaging business necessitated the
expansion of certain borrowing capacities within the Company. A line of
credit was established, with a three-year term, in the amount of $75
million to facilitate the purchase of this business. Approximately $43
million of the line was utilized to purchase the businesses and to either
restructure or repay some of the acquired businesses' debt. Management is
reviewing the on-going capital requirements for the Medical Imaging
business, and management has commitments to spend approximately $14 million
to purchase equipment or upgrade facilities. The Radiopharmacy business is
not capital intensive. There are no signed agreements to further expand
either the Radiopharmacy or Medical Imaging businesses. However, management
is continuing to examine potential acquisitions where the terms are
favorable and may conclude some acquisitions during the next year.
Financing any future acquisitions will either come from internal sources or
additional borrowings on the line of credit. Approximately $29 million
remains unused on the line of credit. Management believes that the Company
has sufficient internal resources or the ability to access capital through
either debt or equity markets to fund any business expansion or internal
capital growth needs.
YEAR 2000
Like many other companies, the Year 2000 computer issue creates risk for
the Company. If the Company's computer systems do not correctly recognize
date information when the year changes to 2000, there could be an adverse
impact on the Company's operations. The Company has therefore initiated a
comprehensive project to prepare its computer systems for the year 2000.
CORPORATE SYSTEMS. Migration & Legacy Systems. The Company's financial
information systems include an SAP system implemented in 1997. This system
has been vendor certified to be "Year 2000" compliant. The Company has
conducted and continues to conduct periodic tests of this system. The
Company analyzed its remaining computer systems to identify any potential
Year 2000 issues, and took appropriate corrective action based on the
results of such analysis. This effort was completed as of late February
1999.
PHARMACY SERVICES FIELD-BASED IT SYSTEMS AND RELATED COMPANY-SUPPLIED
CUSTOMER IT SYSTEMS. The Company's domestic field based pharmacy system has
been modified, tested, and fully deployed as of late February 1999. This
system is believed to be Year 2000 compliant. The Company's international
field-based system is being replaced by a newer Year 2000 compliant system.
Development efforts for this new system are underway and are expected to be
completed by late August 1999. All IT systems supplied by the Company for
use by customers in their locations were either designed as Year 2000
compliant, or customers have been offered the opportunity to convert to a
Year 2000 compliant system. The full and complete implementation of such
conversions is dependent, however, on customer cooperation. The Company
expects this rollout to be substantially completed by mid-1999. The
estimated cost of such modifications to field and customer-installed
systems, including amounts spent to date, is $250,000.
RESIDUAL SYSTEMS & MEDICAL IMAGING BUSINESS. The effort to determine the
Year 2000 compliance of residual systems (i.e. software supplied by
external vendors and other "embedded" systems), including medical imaging
equipment and systems, is estimated to be completed prior to year-end 1999.
The imaging systems are critical to Medical Imaging's business and may
require replacement of certain equipment or systems or hardware upgrades,
in addition to those scheduled and budgeted for upgrade/replacement in the
ordinary course of business.
Many of the vendor-supplied residual systems are small (e.g., alarm
systems, postage meters, etc.), while some are more sophisticated (e.g.,
desktops, desktop applications, and LAN applications). The estimated cost
of such Year 2000 driven modifications/replacements to residual systems and
Medical Imaging's business systems, including amounts spent to date, is not
expected to exceed $750,000. This effort is scheduled to be completed in
the third quarter of 1999.
RISK ASSESSMENT; CONTINGENCY PLANNING. The Company is also in contact
with suppliers, customers, other vendors and fiscal payers, including
federal and state governments, Medicare fiscal intermediaries, insurance
companies and managed care companies to determine the state of their Year
2000 compliance and to assess the potential impact on the Company's
operations if key third parties are not successful in converting their
systems in a timely manner. Risk assessment, readiness evaluation, action
plans, testing with major suppliers, and contingency plans related to these
third parties are expected to be completed by middle of calendar 1999.
Notwithstanding the foregoing, there can be no assurance that another
entity's failure to ensure Year 2000 capability would not have an adverse
effect on the Company.
The Company's risk management program includes emergency backup and
recovery procedures to be followed in event of failure of a business-
critical system. These procedures will be expanded to include specific
procedures for potential Year 2000-related interruptions. These plans will
be completed by middle of calendar 1999.
The costs of the Company's Year 2000 readiness and the dates on which
the Company believes it will complete the Year 2000 modifications are based
on management's best estimates, which were derived utilizing numerous
assumptions of future events, including the continued availability of
certain resources and other factors. However, there can be no guarantee
that these estimates will be achieved and actual results could differ
materially from those anticipated. Specific factors that might cause such
material differences include, but are not limited to, the availability and
cost of personnel trained in this area, the ability to locate and correct
all relevant computer codes, unforeseen circumstances causing the Company
to allocate its resources elsewhere, and similar uncertainties.
Additionally, as testing of Year 2000 functionality of the Company's
systems must occur in a simulated environment, the Company will not be able
to test full system Year 2000 interfaces and capabilities prior to Year
2000. The Company believes that the cost of its Year 2000 compliance
projects over the next two years will not have a material effect on the
Company's financial position or overall trends in results of operations.
NEW ACCOUNTING STANDARDS
The Company will be required to adopt SFAS No. 133, "Accounting for
Derivative Instruments and Hedging Activities". SFAS No. 133 establishes
standards for reporting financial and descriptive information regarding
derivatives and hedging activity. Since the Company does not have any
derivative instruments, this standard will have no impact on the Company's
financial position or results of operations.
SAFE HARBOR STATEMENT
Statements which are not historical facts, including statements about
our confidence, strategies and expectations, opportunities, industry and
market growth, demand and acceptance of new and existing products, and
return on investments are forward looking statements that involve risks and
uncertainties, including without limitation, the effect of general economic
and market conditions, supply and demand for our products, competitor
pricing, maintenance of our current market position and other factors.
Given these uncertainties, undue reliance should not be placed on such
forward-looking statements.
<TABLE>
<CAPTION>
CONSOLIDATED BALANCE SHEETS
DECEMBER 31, DECEMBER 31,
(IN THOUSANDS EXCEPT PER SHARE DATA) 1998 1997
__________________________________________________________________________________________
ASSETS
Current Assets:
<S> <C> <C>
Cash and cash equivalents $ 13,824 $ 25,538
Short-term investments 4,707 2,583
Trade receivables, less allowance for doubtful
accounts of $765 and $1,040, respectively 65,055 54,972
Patient receivables, less allowance for doubtful
accounts of $3,009 10,724 -
Inventory 11,495 5,574
Prepaids and other current assets 12,780 3,913
_______________________________________________________________________________________
Total current assets 118,585 92,580
Marketable investment securities 1,191 1,180
Property and equipment, net 49,103 28,870
Excess of purchase price over net assets acquired, net of
accumulated amortization of $7,642 and $5,354, respectively 62,654 14,319
Other 25,034 27,614
_______________________________________________________________________________________
$256,567 $164,563
=======================================================================================
LIABILITIES AND STOCKHOLDERS' EQUITY
Current Liabilities:
Accounts payable $ 44,578 $ 34,755
Accrued liabilities 7,005 4,353
Accrued wages and related costs 12,563 13,680
Federal and state taxes payable 1,293 1,129
Current maturities of long-term debt 9,122 3,978
_______________________________________________________________________________________
Total current liabilities 74,561 57,895
_______________________________________________________________________________________
Long-term debt, net of current maturities 70,322 17,332
Deferred compensation 311 1,969
Stockholders' Equity:
Common stock $.05 par value; authorized 20,000 shares;
issued 12,517 and 11,435 shares at December 31,
1998 and 1997, respectively 626 572
Additional paid-in capital 72,622 55,061
Notes receivable from related parties (9,028) -
Accumulated other comprehensive income (527) (330)
Employee savings and stock ownership loan guarantee (5,056) (6,741)
Retained earnings 65,260 51,329
Treasury stock, at cost, 1,356 shares
at December 31, 1998 and 1997 (12,524) (12,524)
_______________________________________________________________________________________
Total stockholders' equity $111,373 $ 87,367
_______________________________________________________________________________________
$256,567 $164,563
See accompanying Notes to Consolidated Financial Statements
</TABLE>
<TABLE>
<CAPTION>
CONSOLIDATED STATEMENTS OF INCOME
YEAR ENDED YEAR ENDED YEAR ENDED
DECEMBER 31, DECEMBER 31, DECEMBER 31,
(IN THOUSANDS EXCEPT PER SHARE DATA) 1998 1997 1996
____________________________________________________________________________________________________
<S> <C> <C> <C>
Net sales $449,023 $380,563 $366,447
Cost of sales 317,073 290,398 286,254
___________________________________________
Gross profit 131,950 90,165 80,193
Operating, selling and administrative expenses 92,146 67,214 61,151
Depreciation and amortization 15,254 9,939 10,385
___________________________________________
Operating income 24,550 13,012 8,657
Other income (expense):
Interest income 1,643 1,324 1,703
Interest expense (5,291) (1,207) (845)
Other, net 3,283 3,826 1,796
___________________________________________
Other income (expense), net (365) 3,943 2,654
Income from continuing operations before income taxes 24,185 16,955 11,311
Provision for income taxes 10,254 6,923 4,411
___________________________________________
Income from continuing operations 13,931 10,032 6,900
Discontinued operations, net of taxes - 1,063 (2,264)
___________________________________________
Net income $ 13,931 $ 11,095 $ 4,636
===========================================
Net income per share - basic:
Income from continuing operations $ 1.30 $ 1.00 $ .66
Discontinued operations, net of taxes - .11 (.22)
___________________________________________
Net income $ 1.30 $ 1.11 $ .44
===========================================
Weighted average shares outstanding 10,726 9,998 10,424
===========================================
Net income per share - diluted:
Income from continuing operations $ 1.23 $ .98 $ .65
Discontinued operations, net of tax benefit - .10 (.21)
___________________________________________
Net income $ 1.23 $ 1.08 $ .44
===========================================
Weighted average shares outstanding 11,339 10,282 10,629
===========================================
See accompanying Notes to Consolidated Financial Statements
</TABLE>
<TABLE>
<CAPTION>
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY AND COMPREHENSIVE INCOME
ACCUMULATED OTHER
COMPREHENSIVE INCOME
_______________________
EMPLOYEE
SAVINGS & NOTES
STOCK FOREIGN RECEIVABLE
ADDITIONAL OWNERSHIP UNREALIZED CURRENCY FROM TOTAL
COMMON STOCK PAID-IN LOAN LOSS ON TRANSLATION RETAINED TREASURY RELATED STOCKHOLDERS'
(IN THOUSANDS) SHARES AMOUNT CAPITAL GUARANTEE INVESTMENT ADJUSTMENT EARNINGS STOCK PARTIES EQUITY
_________________________________________________________________________________________________________________________________
<S> <C> <C> <C> <C> <C> <C> <C> <C> <C> <C>
Balance at December 31, 1995 10,412 $533 $47,169 $(2,998) $ (24) $(105) $35,598 $(1,911) $ - $78,262
Issuance of common stock 679 34 4,268 4,302
Issuance of treasury stock 250 (72) 2,854 2,782
Tax benefit from the exercise
of stock options 1,707 1,707
Reacquisition of common stock
for treasury (1,126) (11,556) (11,556)
ESSOP loan guarantee (2,781) (2,781)
Amortization of loan guarantee 1,235 1,235
Comprehensive Income:
Unrealized loss on investments (3)
Foreign currency translation
adjustment (52)
Net income 4,636
Total Comprehensive Income: 4,581
________________________________________________________________________________________________________________________________
Balance at December 31, 1996 10,215 $567 $53,072 $(4,544) $ (27) $(157) $40,234 $(10,613) $ - $78,532
Issuance of common stock 94 5 1,754 1,759
Issuance of treasury stock 250 2,599 2,599
Tax benefit from the exercise
of stock options 235 235
Reacquisition of common stock
for treasury (480) (4,510) (4,510)
Amortization of loan guarantee 1,366 1,366
ESSOP loan guarantee (3,563) (3,563)
Comprehensive Income:
Unrealized gain on investments 10
Foreign currency translation
adjustment (156)
Net income 11,095
Total Comprehensive Income: 10,949
________________________________________________________________________________________________________________________________
Balance at December 31, 1997 10,079 $572 $55,061 $(6,741) $ (17) $(313) $51,329 $(12,524) $ - $87,367
Issuance of common stock 1,082 54 17,116 $(9,028) 8,142
Tax benefit from the exercise
of stock options 445 445
Amortization of loan guarantee 1,685 1,685
Comprehensive Income:
Unrealized loss on investments (300)
Foreign currency translation
adjustment 103
Net income 13,931
Total Comprehensive Income: 13,734
________________________________________________________________________________________________________________________________
Balance at December 31, 1998 11,161 $626 $72,622 $(5,056) $(317) $(210) $65,260 $(12,524) $(9,028) $111,373
================================================================================================================================
See accompanying Notes to Consolidated Financial Statements
</TABLE>
<TABLE>
<CAPTION>
CONSOLIDATED STATEMENTS OF CASH FLOWS
YEAR ENDED YEAR ENDED YEAR ENDED
DECEMBER 31, DECEMBER 31, DECEMBER 31,
(IN THOUSANDS) 1998 1997 1996
_____________________________________________________________________________________________________
<S> <C> <C> <C>
Cash flows from operating activities:
Net income $ 13,931 $ 11,095 $ 4,636
Adjustments to reconcile net income to net cash provided by
operating activities:
Depreciation and amortization 15,254 9,939 10,385
Provision for losses on receivables 2,734 129 (186)
Amortization of loan guarantee 1,685 1,366 1,235
Decrease (increase) in:
Accounts receivable - trade (9,459) (3,237) (923)
Accounts receivable - patient (1,401)
Inventory (5,935) 2,336 (2,674)
Prepaids and other current assets (2,223) 1,699 (3,220)
Net assets of discontinued operations - 1,198 (1,198)
Other assets (4,846) (8,368) (4,833)
Increase (decrease) in:
Accounts payable 5,566 (4,012) 5,553
Accrued liabilities (456) 998 220
Accrued wages and related costs (1,110) 2,927 695
Federal and state taxes payable 630 (931) 3,236
Deferred compensation (1,658) (2) 1,107
______________________________________
Net cash provided by operating activities 12,712 15,137 14,033
Cash flows from investing activities:
Purchase of property and equipment, net (15,986) (10,889) (8,107)
Payments for acquisitions (45,338) (6,550) -
Net decrease (increase) in short-term investments (2,124) (1,323) 1,038
Net decrease (increase) in long-term investments (11) 59 2
Unrealized gain (loss) in investments (300) 10 (3)
______________________________________
Net cash used in investing activities (63,759) (18,693) (7,070)
Cash flows from financing activities:
Issuance of common stock 3,142 1,759 4,302
Issuance of treasury stock - 2,599 2,782
Reacquisition of common stock - (4,510) (11,556)
Increase in ESSOP loan guarantee - (3,563) (2,781)
Proceeds from long-term debt 46,271 10,634 4,930
Repayment of long-term debt (10,070) (2,807) (2,435)
______________________________________
Net cash provided by (used in) financing activities 39,343 4,112 (4,758)
______________________________________
Net (decrease) increase in cash and cash equivalents (11,704) 556 2,205
Effect of exchange rate on cash (10) (232) (13)
Cash and cash equivalents at beginning of period 25,538 25,214 23,022
______________________________________
Cash and cash equivalents at end of period $13,824 $25,538 $25,214
=======================================
See accompanying Notes to Consolidated Financial Statements
</TABLE>
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
PRINCIPLES OF CONSOLIDATION: The Company's business is primarily
concentrated in two business segments. First is the compounding, dispensing
and distributing of radiopharmaceuticals to hospitals and clinics. The
second is the management and provision of medical diagnostic imaging
services. The consolidated financial statements include the assets,
liabilities and operations of the Company and its subsidiaries. All
significant intercompany accounts and transactions have been eliminated in
consolidation.
CASH AND CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS: The Company considers
all highly liquid investments purchased with an original maturity of three
months or less to be cash equivalents. Short-term investments consist
principally of time deposits and tax-exempt municipal securities and are
carried at cost, which approximates market value.
FINANCIAL INSTRUMENTS: The carrying value of financial instruments such as
cash and cash equivalents, trade receivables, payables and floating rate
short and long-term debt, approximate their fair value.
PATIENT RECEIVABLES: The Company receives payment for services rendered
from federal and state agencies (under the Medicare, Medicaid and Champus
programs), managed health care plans, commercial insurance companies,
employers and patients. During the year ended December 31, 1998
approximately 9.4% of the Company's patient revenues related to patients
participating in the Medicare and Medicaid programs. The Company does not
believe that there are any other significant concentrations of revenues
from any particular payer that would subject the Company to any significant
credit risk in the collection of its patient accounts receivable.
INVENTORY: Inventories, consisting of purchased products, are stated at the
lower of cost (first-in, first-out) or market.
PROPERTY AND EQUIPMENT: Property and equipment are stated at cost and
depreciated or amortized on a straight-line basis over estimated useful
lives ranging from two to fifteen years.
SELF INSURANCE: The Company historically has purchased insurance in excess
of self-insured retentions or deductibles for losses and liabilities
related to vehicle claims, medical claims and general product liability
claims. Losses accrued under self-insured and deductible plans are based
upon the Company's estimates of aggregated liability claims incurred using
certain actuarial assumptions followed in the insurance industry and the
Company's own experience.
EXCESS OF PURCHASE PRICE OVER NET ASSETS ACQUIRED: The cost in excess of
net assets of acquired businesses is being amortized on a straight-line
basis over periods of 15 to 40 years. The Company periodically evaluates
the carrying value of these assets and, accordingly, considers the ability
to generate positive cash flow through projected undiscounted future
operating cash flows from the related operation as the key factor in
determining whether the assets have been impaired. The Company's accounting
treatment is consistent with Statement of Financial Accounting Standard
(SFAS) No.121, "Accounting for the Impairment of Long-Lived Assets and for
Long-Lived Assets to be Disposed of."
MARKETABLE INVESTMENT SECURITIES: Marketable investment securities consist
primarily of corporate debt and United States government obligations. The
Company classifies its debt and marketable equity securities in one of
three categories: trading, available-for-sale or held-to-maturity. Trading
securities are bought and held principally for the purpose of selling them
in the near term. Held-to-maturity securities are those securities that the
Company has the ability and intent to hold until maturity. All other
securities not included in trading or held-to-maturity are classified as
available-for-sale.
Held-to-maturity securities are recorded at amortized cost, adjusted for
the amortization or accretion of premiums or discounts. Unrealized holding
gains and losses on trading securities are included in earnings. Unrealized
holding gains and losses, net of the related tax effect, on available-for-
sale securities are excluded from earnings and are reported as a component
of accumulated other comprehensive income until realized.
FOREIGN CURRENCY TRANSLATION: Assets and liabilities of foreign operations
are translated into U.S. dollars based upon the prevailing exchange rates
in effect at the balance sheet date. Foreign exchange gains and losses
resulting from these translations are included as a component of
accumulated other comprehensive income. Actual gains or losses incurred on
currency transactions in other than the country's functional currency are
included in net income currently.
STOCK OPTIONS: The Company measures stock-based compensation using the
intrinsic value method which assumes that options granted at market price
at the date of grant have no intrinsic value. In accordance with SFAS No.
123, "Accounting for Stock-Based Compensation," proforma net income and
earnings per share are presented in Note 9 as if the fair value method had
been applied.
INCOME TAXES: Income taxes are accounted for under the asset and liability
method. Deferred tax assets and liabilities are recognized for the future
tax consequences attributable to differences between the financial
statement carrying amounts of existing assets and liabilities and their
respective tax bases. Deferred tax assets and liabilities are measured
using enacted tax rates expected to apply to taxable income in the years in
which those temporary differences are expected to be recovered or settled.
The effect on deferred tax assets and liabilities of a change in tax rates
is recognized in income in the period that includes the enactment date.
REVENUES: The Company's medical imaging facilities have entered into
agreements with third-party payers, including government programs and
managed care health care plans, under which the facilities are paid based
upon established charges, predetermined rates per service or discounts from
established charges.
Revenues are recorded at estimated amounts due from patients and third-
party payers for the services provided. Management believes that adequate
provisions have been made for adjustments.
USE OF ESTIMATES: Management of the Company has made a number of estimates
and assumptions relating to the reporting of assets and liabilities, the
reporting of sales and expenses and the disclosure of contingent assets and
liabilities to prepare these financial statements in conformity with
generally accepted accounting principles. Actual results could differ from
those estimates.
NEW ACCOUNTING STANDARDS: The Company will be required to adopt SFAS No.
133, "Accounting for Derivative Instruments and Hedging Activities". SFAS
No. 133 establishes standards for reporting financial and descriptive
information regarding derivatives and hedging activity. Since the Company
does not have any derivative instruments, this standard will have no impact
on the Company's financial position or results of operations.
RECLASSIFICATIONS: Certain items in the prior years' consolidated financial
statements have been reclassified to conform to the current year's
presentation.
PRE-OPENING COSTS: In 1998 the Company adopted the Statement of Position
98-5, "Reporting on the Cost of Start-up Activities" which requires the
costs of start-up activities be expensed as incurred. As of December 31,
1998, all previously capitalized pre-opening costs had been fully
amortized.
2. ACQUISITIONS AND DISCONTINUED OPERATIONS
In March 1997, the Company acquired certain assets of Golden
Pharmaceuticals, Inc. relating to Iodine-123, including the building and
equipment used to manufacturer Iodine-123 and the approved New Drug
Application for Iodine-123 capsules, for $6.5 million in cash and a
promissory note for $150,000. This transaction has been accounted for as a
purchase.
The results of operations related to the above transaction is included
in the Company's consolidated financial statements from the effective
acquisition dates. The transaction is not included in the pro forma
results of operation, since it was not material.
On May 6, 1997, the Company completed the sale of its interest in
P.E.T.Net(TM) Pharmaceutical Services(TM), LLC ("P.E.T.Net") to PETNet
Partners, LLC, an affiliate of the Company's former joint venture partner
CTI, Inc. Consideration received included a secured note of $2.25 million
and royalties of up to $1.5 million based on P.E.T.Net's future sales.
Additionally, Syncor is the preferred distributor of positron emission
tomography isotopes for all existing and future P.E.T.Net sites and has
exclusive distribution rights for cyclotrons, manufactured by CTI, Inc., in
Taiwan for two years. All costs associated with the Company's operation and
disposal of its interest in P.E.T.Net from December 31, 1996 to March 18,
1997, the date the sale agreement was entered into, were included in the
results of operations for 1996. The Company recorded a gain on sale of the
discontinued operations of approximately $1.1 million, net of taxes of $0.7
million, during 1997.
During 1998, the Company acquired three companies in the medical imaging
business. The first of these transactions occurred in January when Syncor
acquired the medical imaging business from National Diagnostic Services,
Inc. and an affiliate ("NDS"). The purchase price for the acquisition was
$12 million including the assumption of $4.3 million in debt. The acquired
business included nine medical imaging centers owned or managed by NDS.
Also in January 1998, a subsidiary of Syncor merged with and into TME,
Inc., a company based in Houston, Texas, pursuant to which TME, Inc. became
a wholly owned subsidiary of Syncor. TME owns, operates and/or manages
free-standing medical imaging centers through joint ventures and
partnerships. It has 20 facilities in its network. As consideration for the
merger, Syncor paid $14.5 million in cash to TME's stockholders and assumed
$5.2 million in TME liabilities.
In March 1998 Syncor acquired the medical imaging business of
International Magnetic Imaging, Inc., a subsidiary of Consolidated
Technology Group Ltd. The acquired business included ten outpatient medical
imaging centers and an imaging referral network operating in 35 states. The
purchase price for the acquisition was $20.4 million, plus the assumption
of $24.3 million in liabilities and trade payables.
These 1998 acquisitions were all completed on or about the end of first
quarter of 1998 and now operate, along with the Open MRI business, under
the subsidiary named Comprehensive Medical Imaging, Inc. The Company
accounted for these transactions as a purchase and the purchase prices were
allocated to fixed assets, non-compete and consulting agreements and
goodwill. Goodwill for the first two acquisitions is being amortized over a
period of 20 years while the IMI acquisition is being amortized over 30
years. The results of operations related to the above 1998 transactions
are included in the Company's consolidated financial statements from the
effective acquisition dates.
The following unaudited pro forma information presents a summary of our
consolidated results of operation and imaging center businesses as if the
acquisition had occurred on January 1, 1997:
<TABLE>
<CAPTION>
FISCAL YEAR
(IN MILLIONS, EXCEPT PER SHARE) 1998 1997
_____________________________________________________________________________
<S> <C> <C>
Sales $457,757 $423,719
Net Earnings $ 13,748 $ 10,902
Net Earnings per diluted share (continuing operations) $ 1.21 $ 1.06
_____________________________________________________________________________
</TABLE>
These unaudited proforma results have been prepared for comparative
purposes only and do not purport to be indicative of the results of
operations that would have occurred or the future results of operations of
the consolidated entities.
On December 31, 1998 the Company entered into an agreement to sell its
partnership interest in the Imaging Center of Orlando ("ICO") to Kaley
Imaging, Inc. ("Kaley"). Kaley purchased the Company's interest in ICO for
a secured note of $1.25 million. This transaction resulted in a pre-tax
gain on sale of $1.1 million and an after tax gain of $.6 million, or $.05
per share on a diluted basis in the fourth quarter. This gain was recorded
in "Other income, Other-net" for financial statement presentation.
3. PROPERTY AND EQUIPMENT, NET
The major classes of property are:
<TABLE>
<CAPTION>
DECEMBER 31, DECEMBER 31,
(IN THOUSANDS) 1998 1997
___________________________________________________________________________
<S> <C> <C>
Land and buildings $ 6,098 $ 4,312
Furniture and equipment 74,866 50,254
Leasehold improvements 17,077 12,654
___________________________________________________________________________
98,041 67,220
Less accumulated depreciation and amortization 48,938 38,350
___________________________________________________________________________
$49,103 $28,870
===========================================================================
</TABLE>
4. MARKETABLE INVESTMENT SECURITIES
Marketable investment securities consist of:
<TABLE>
<CAPTION>
DECEMBER 31, DECEMBER 31,
(IN THOUSANDS) 1998 1997
___________________________________________________________________________
<S> <C> <C>
Available-for-sale, at fair value, net of tax effect $ 691 $ 680
Held-to-maturity, at amortized cost 500 500
___________________________________________________________________________
$1,191 $1,180
===========================================================================
</TABLE>
The amortized cost, gross unrealized holding gains and losses and fair
value for available-for-sale and held-to-maturity securities by major
security type at December 31, 1998 and 1997 were as follows:
<TABLE>
<CAPTION>
1998 UNREALIZED
AMORTIZED HOLDING HOLDING FAIR
(IN THOUSANDS) COST GAINS LOSSES VALUE
___________________________________________________________________________
<S> <C> <C> <C> <C>
Available-for-sale:
Corporate debt securities $697 $ 44 $(50) $691
___________________________________________________________________________
Held-to-maturity: -
U.S. Treasury securities 500 - 500
___________________________________________________________________________
$1,197 $ 44 $(50) $1,191
===========================================================================
1997 UNREALIZED
AMORTIZED HOLDING HOLDING FAIR
(IN THOUSANDS) COST GAINS LOSSES VALUE
___________________________________________________________________________
Available-for-sale:
Corporate debt securities $697 $ 30 $(47) $680
___________________________________________________________________________
Held-to-maturity:
U.S. Treasury securities 500 - - 500
___________________________________________________________________________
$1,197 $ 30 $(47) $1,180
===========================================================================
</TABLE>
The unrealized holding losses on held-to-maturity securities have not been
recognized in the accompanying consolidated
financial statements.
Maturities of investment securities classified as available-for-sale and
held-to-maturity were as follows at December 31, 1998 and 1997:
<TABLE>
<CAPTION>
1998 1997
AMORTIZED FAIR AMORTIZED FAIR
(IN THOUSANDS) COST VALUE COST VALUE
_________________________________________________________________________________________
<S> <C> <C> <C> <C>
Available-for-sale:
Due after one year through five years $499 $490 $ - $ -
Due after five years through ten years $198 $201 $499 $485
Due after ten years $ - $ - $198 $195
Held-to-maturity
Due within one year $500 $500 $500 $500
==========================================================================================
</TABLE>
5. LINE OF CREDIT
At December 31, 1998, the Company had an unsecured revolving line of
credit for short-term borrowings aggregating $75,000,000. The terms of this
revolving credit line include two interest rate borrowing options, the
Eurodollar rate plus an applicable margin or the bank's Prime rate (7.75
percent at Dec. 31, 1998). As of December 31, 1998, the availability of the
line of credit was reduced by $810,000 as a result of outstanding standby
letters of credit. To maintain this line of credit, the Company is required
to pay a quarterly commitment fee of 1/4 of one percent per annum on the
unused portion.
The line of credit agreement specifies that certain covenants (including
limitations on investments and acquisitions, new borrowings and issuance of
new stock) be maintained. Certain financial ratios (including EBITA ratio
and Fixed charge coverage ratio) also need to be maintained under this
agreement. As of December 31, 1998, the Company was in compliance with all
debt covenants under the credit line agreement.
6. LONG TERM DEBT
The Company's long-term debt was as follows:
<TABLE>
<CAPTION>
DECEMBER 31, DECEMBER 31,
(IN THOUSANDS) 1998 1997
__________________________________________________________________________________________________
<S> <C> <C>
Capital lease obligations, payable in varying installments
through 2003, with interest rates ranging from 10% to 12% $ 312 $ 4,094
__________________________________________________________________________________________________
Notes payable, unsecured, payable in installments through 2012,
with effective interest rates ranging from 6% to 12.75% 508 1,160
__________________________________________________________________________________________________
Note payable, unsecured, payable in installments through 2001,
with a floating interest rate of either the lower of prime or
LIBOR plus .75%, 5.91% and 6.66% at December 31, 1998 and 1997 5,056 6,741
__________________________________________________________________________________________________
Notes payable, secured, payable in installments through 2003,
with a non-interest bearing rate, net of unamortized discount
at 6% to 10% of $212 and $384 at December 31, 1998
and 1997, respectively 2,554 2,815
__________________________________________________________________________________________________
Note payable, unsecured, payable in installments through 2002,
with a floating interest rate of LIBOR plus .95%, 6.20% and
6.80% at December 31, 1998 and 1997 respectively 6,500 6,500
__________________________________________________________________________________________________
Note payable, unsecured, payable in lump sum on January 5, 2001
with a floating interest rate of LIBOR plus 1.25% or prime rate,
with interest rates ranging from 6.23% to 7.75% 46,000 0
__________________________________________________________________________________________________
Capital Lease obligations, payable in varying installments through
2003, with interest rates ranging from 5% to 17% 2,540 0
__________________________________________________________________________________________________
Notes Payable, payable in varying installments through 2002
with effective interest rates ranging from 6% to 11.5% 10,703 0
__________________________________________________________________________________________________
Non-Compete agreement paid in varying installments
with an effective interest rate of 6% 856 0
__________________________________________________________________________________________________
Capital Lease obligations, payable in installments through 2002,
with effective interest rates from 9.5% to 10% 4,415 0
__________________________________________________________________________________________________
Total debt 79,444 21,310
__________________________________________________________________________________________________
Less current maturities of long-term debt 9,122 3,978
__________________________________________________________________________________________________
Long-term debt, net of current maturities $70,322 $17,332
==================================================================================================
</TABLE>
At December 31, 1998, long-term debt maturing over the next five
years is as follows: 1999, $9,122; 2000, $7,055; 2001, $51,926; 2002,
$7,047; 2003, $926 and $3,368 thereafter.
Interest paid was $5,392, $1,205 and $834 for the years ended
December 31, 1998, 1997 and 1996.
7. INCOME TAXES
Total income tax expense for the years ended December 31, 1998 and
1997 was allocated as follows:
<TABLE>
<CAPTION>
YEAR ENDED YEAR ENDED
DECEMBER 31, DECEMBER 31,
(IN THOUSANDS) 1998 1997
__________________________________________________________________________________________
<S> <C> <C>
Income from continuing operations $10,254 $6,923
Stockholders' equity for compensation expense for tax purposes
in excess of amounts recognized for financial reporting (444) (235)
__________________________________________________________________________________________
$ 9,810 $6,688
==========================================================================================
</TABLE>
Income tax expense (benefit) attributable to income from continuing operations
consisted of:
<TABLE>
<CAPTION>
YEAR ENDED YEAR ENDED YEAR ENDED
DECEMBER 31, DECEMBER 31, DECEMBER 31,
(IN THOUSANDS) 1998 1997 1996
______________________________________________________________________
<S> <C> <C> <C>
Current:
Federal $ 8,022 $ 6,839 $ 5,758
State 1,715 1,262 883
______________________________________________________________________
9,737 8,101 6,641
Deferred:
Federal 625 (916) (2,101)
State (108) (262) (129)
______________________________________________________________________
517 (1,178) (2,230)
______________________________________________________________________
$10,254 $ 6,923 $ 4,411
======================================================================
</TABLE>
The amounts differed from the amounts computed by applying the federal income
tax rate of 35 percent to pretax income from continuing operations as a result
of the following:
<TABLE>
<CAPTION>
YEAR ENDED YEAR ENDED YEAR ENDED
DECEMBER 31, DECEMBER 31, DECEMBER 31,
(IN THOUSANDS) 1998 1997 1996
__________________________________________________________________________________________________
<S> <C> <C> <C>
Federal income taxes at "expected" rate $ 8,465 $ 5,935 $ 3,959
Increase (reduction) in income taxes resulting from:
Meals and entertainment 205 213 188
Tax exempt interest (95) (109) (106)
Amortization of intangible assets 343 143 143
Foreign losses 789 370 -
State taxes, net of Federal benefit 1,045 650 490
Utilization of general business credits (578) (235) (228)
Other 80 (44) (35)
__________________________________________________________________________________________________
$10,254 $ 6,923 $4,411
==================================================================================================
</TABLE>
The tax effect of temporary differences that give rise to significant portions
of the deferred tax assets and deferred tax liabilities at December 31, 1998
and 1997, are presented below:
<TABLE>
<CAPTION>
DECEMBER 31, DECEMBER 31,
(IN THOUSANDS) 1998 1997
___________________________________________________________________________________________________
<S> <C> <C>
Deferred tax assets:
Net operating loss carryforwards $ 394 $ -
Compensated absences, principally due to accrual
for financial reporting purposes 1,376 1,492
Accounts receivable, due to allowance for doubtful accounts 1,758 400
Accrued liabilities, primarily due to self-insurance and other
contingency accruals for financial reporting purposes 2,169 1,052
Deferred compensation, due to accrual for financial reporting purposes 3,100 2,507
Covenant not to compete due to difference in amortization 644 522
Plant and equipment, due to difference in depreciation - 383
Deferred start-up expenses - 389
Other 592 244
__________________________________________________________________________________________________
Total gross deferred tax asset $10,033 $6,989
Deferred tax liabilities:
Plant and equipment, due to difference in depreciation $ 522 $ -
Partnership basis, due to book to tax differences at partnership level 1,110 -
Deferred expenses 120 -
Goodwill due to difference in amortization 424 74
Other 129 384
__________________________________________________________________________________________________
Total gross deferred tax liabilities 2,305 458
__________________________________________________________________________________________________
Net deferred tax asset $ 7,728 $6,531
==================================================================================================
</TABLE>
Management has reviewed the recoverability of deferred income tax assets
and has determined that it is more likely than not that the deferred tax
assets will be fully realized through future taxable earnings.
Income tax payments amounted to $9,013, $7,622 and $5,222 for the
years ended December 31, 1998, 1997 and 1996, respectively.
8. COMMITMENTS
The Company leases facilities, vehicles and equipment with terms
ranging from three years to fifteen years. The majority of property
leases contain renewal options and some have escalation clauses for
increases in property taxes, Consumer Price Index and other items.
The Company leases a building and certain items of equipment under
capital leases which had an approximate cost of $13,148, $6,891, and
$2,598, at December 31, 1998, 1997 and 1996 and accumulated depreciation
of $4,702, $2,181, and $1,942, respectively. The Company was not
utilizing this building and, accordingly, sublet it to a third party for
the balance of the lease term. The cost increase over the prior year was
due to the acquisition of the medical imaging businesses of CMI and
their related capital leases.
Future minimum lease payments under capital leases and noncancelable
operating leases with terms greater than one year and related sublease
income were as follows at December 31, 1998:
<TABLE>
<CAPTION>
CAPITAL OPERATING SUBLEASE
(IN THOUSANDS) LEASES LEASES INCOME
______________________________________________________________________________
<S> <C> <C> <C>
Year ending December 31,
1999 $ 2,885 $ 7,771 $ 317
2000 2,005 5,152 75
2001 1,766 3,859 -
2002 1,486 3,450 -
2003 519 2,867 -
Thereafter 0 6,112 -
______________________________________________________________________________
$ 8,661 $29,211 $ 392
==============================================================================
Less amount representing interest (1,394)
_________________________________________________________
Present value of net minimum lease payments $ 7,267
=========================================================
</TABLE>
Rental expense under operating leases was $8,199, $7,528 and $6,579
for the years ended December 31, 1998, 1997 and 1996, respectively.
9. STOCK OPTIONS AND RIGHTS
Options to purchase common stock have been granted under various
plans to officers, directors and other key employees at prices equal to
the market prices at date of grant. An aggregate of 4,093,913 shares of
stock have been authorized for issuance under the various plans as of
December 31, 1998. Options are generally exercisable at a rate of 25
percent per year beginning one year from the date of grant and expire
ten years after the date of grant. At December 31, 1998, 1,244,393
shares are reserved for issuance under the various plans.
The per share weighted-average fair value of stock options granted
during 1998, 1997 and 1996 was $11.34, $5.74 and $6.96, respectively, on
the date of grant using the Black Scholes option-pricing model with the
following weighted-average assumptions: 1998 - expected dividend yield
of 0%; risk-free interest rate of 4.8%; expected volatility of 60.4% and
an expected life of 5.19 years; 1997 - expected dividend yield of 0%;
risk-free interest rate of 5.71%; expected volatility of 61.1% and an
expected life of 5.26 years; 1996 - expected dividend yield of 0%; risk-
free interest rate of 6.21%; expected volatility of 60.1% and an
expected life of 5.10 years.
The Company applies APB Opinion No. 25 in accounting for its plans
and, accordingly, no compensation cost has been recognized for its stock
options in the Consolidated Statements of Operations. Had the Company
determined compensation cost based on the fair value at the grant date
for its stock options under SFAS No. 123, the Company's net income would
have been reduced to the pro forma amounts indicated in the following
table:
<TABLE>
<CAPTION>
DECEMBER 31, DECEMBER 31, DECEMBER 31,
(IN THOUSANDS, EXCEPT PER SHARE DATA) 1998 1997 1996
_________________________________________________________________________________
<S> <C> <C> <C>
Net income
As reported $13,931 $11,095 $ 4,636
Pro forma $11,343 $10,802 $ 4,355
Earnings per share
Basic:
As reported $ 1.30 $ 1.11 $ .44
Pro forma $ 1.06 $ 1.08 $ .42
Diluted:
As reported $ 1.23 $ 1.08 $ .44
Pro forma $ 1.00 $ 1.05 $ .41
=================================================================================
</TABLE>
Pro forma net income only reflects options granted in 1995 and
thereafter. Therefore, the full impact of calculating compensation cost
for stock options under SFAS No. 123 is not reflected in the pro forma
net income amounts presented because compensation cost is reflected over
the options' vesting period of four years and compensation cost for
options granted prior to January 1, 1995 is not considered.
A summary of employee stock options is as follows:
<TABLE>
<CAPTION>
NUMBER OF WEIGHTED AVERAGE
(IN THOUSANDS, EXCEPT SHARE PRICE) SHARES EXERCISE PRICE
______________________________________________________________________
<S> <C> <C>
Outstanding at December 31, 1995 1,540 $ 7.53
Granted 373 $ 12.05
Exercised (676) $ 6.32
Cancelled (91) $ 9.61
______________________________________________________________________
Outstanding at December 31, 1996 1,146 $ 10.03
Granted 401 $ 9.80
Exercised (94) $ 8.47
Cancelled (42) $ 10.68
______________________________________________________________________
Outstanding at December 31, 1997 1,411 $ 10.22
Granted 1,685 $ 16.57
Exercised (204) $ 12.04
Cancelled (43) $ 10.21
______________________________________________________________________
Outstanding at December 31, 1998 2,849 $ 13.7
======================================================================
</TABLE>
At December 31, 1998, the range of exercise prices and weighted
average remaining contractual life of outstanding options was $6.18 to
$23.63 and eight years, respectively.
At December 31, 1998, 1997 and 1996, the number of options
exercisable was approximately 1,004,000, 590,000 and 437,000,
respectively, and the weighted average price of those options was
$11.16, $10.12 and $10.03, respectively.
The Company derives a tax benefit from the options exercised and sold
by employees and the benefit is credited to additional paid-in capital.
In November 1989, the Company made a rights distribution of one
common share purchase right on each outstanding share of common stock.
When exercisable, each right will entitle its holder to buy one-fourth
of a share of the Company's common stock at a price of $5 per share
subject to adjustments (the "Purchase Price"). The rights expire on
September 30, 1999. With certain exceptions, subject to the approval of
the Board of Directors, the rights will become exercisable if a person
("Acquiring Person") has acquired or makes an offer, the consummation of
which will result in beneficial ownership of 20 percent or more of the
Company's general voting power. At such time (the "Distribution Date"),
the rights will be evidenced by the certificates representing the common
shares and will be transferred with and only with the common shares.
Except for certain transactions approved by the Board of Directors, in
the event: (i) the Company is acquired in a merger; (ii) 50 percent or
more of its consolidated assets or earning power is sold; or (iii) any
person becomes an Acquiring Person, proper provisions shall be made so
that each holder of the right (other than rights beneficially owned by
the Acquiring Person) receives, upon the exercise thereof at the
adjusted exercise price of the right, which shall be four times the
Purchase Price, that number of shares of common stock of the acquiring
company in the case of (i) or (ii) above, or of the Company, in the case
of (iii) above, which at the time of such transaction will have a market
value of two times the adjusted exercise price of the right.
10. EMPLOYEE BENEFIT PLANS
The Company's 401(k) plan is open to all employees who are at least
21 years of age and have a minimum of twelve consecutive months of
service. In 1989, the Company's Board of Directors amended the plan to
an Employees Savings and Stock Ownership Plan (ESSOP) to allow the plan
to acquire one million of the Company's shares through a leveraged
employee stock ownership plan transaction. In June 1995, September 1996,
and August 1997, an additional 750,000 shares, in total, which were
purchased in the open market, were contributed to the plan. These shares
were originally classified as "treasury stock." The contributions
totaled $8,657 and reflected the fair market value at the time of
contribution. In connection with these transactions, the Company has
made a loan to the ESSOP. The ESSOP loan had an outstanding balance of
$5,056, at December 31, 1998.
Under the ESSOP, participants may contribute one percent to fourteen
percent of their compensation to 401(k) investment options and an
additional two percent of their compensation to purchase Company stock.
The Company makes matching contributions to 50 percent of the employees'
401(k) investment contributions up to a maximum of four percent of the
employees' compensation and may make matching contributions to 100
percent of the employees' Company stock purchases up to two percent of
the employees' compensation. The Company's matching contribution is made
in cash and reflects the ESSOP loan payment. The number of shares of
stock available to match employee contributions is directly related to
the amount of principal payments made on the ESSOP loan. Once the number
of available shares is determined, the Company matches the employees'
contributions as described above by determining the fair market value of
the available stock. The remainder of any shares not allocated after all
matching is complete will be allocated to all eligible employees based
on relative compensation.
Participants are fully and immediately vested in their contributions
and vest in employer contributions over a five-year period of continuous
employment. After five years of continuous employment, any further
employer contributions are fully and immediately vested. The Company's
contributions for the years ended December 31, 1998, 1997 and 1996
amounted to $2,091, $1,625 and $1,444, respectively, of which $1,685,
$1,366, and $1,235 were used to pay down principal on the ESSOP loan and
$406, $259, and $209 to pay interest.
11. NET INCOME PER SHARE
The following table presents the computation of basic earnings per
share (EPS):
<TABLE>
<CAPTION>
FOR THE YEAR ENDED FOR THE YEAR ENDED FOR THE YEAR ENDED
DECEMBER 31, 1998 DECEMBER 31, 1997 DECEMBER 31, 1996
__________________________________________________________________________________________________________________________________
INCOME SHARES PER SHARE INCOME SHARES PER SHARE INCOME SHARES PER SHARE
(NUMERATOR) (DENOMINATOR) AMOUNT (NUMERATOR) (DENOMINATOR) AMOUNT (NUMERATOR) (DENOMINATOR) AMOUNT
__________________________________________________________________________________________________________________________________
<S> <C> <C> <C> <C> <C> <C> <C> <C> <C>
Income from continuing
operations $13,931 $10,032 $6,900
Basic EPS $13,931 10,726 $1.30 $10,032 9,998 $1.00 $6,900 10,424 $0.66
===== ===== =====
Effect of Dilutive
Stock Options 614 284 205
____ ____ ____
Diluted EPS $13,931 11,339 $1.23 $10,032 10,282 $0.98 $6,900 10,629 $0.65
===== ===== =====
</TABLE>
Options to purchase 64,000 shares of common stock at prices ranging from
$18.00 to $23.62 were outstanding during 1998, but were not included in
the computation of diluted EPS at December 31, 1998 because the options'
exercise prices were greater than the average market price of the common
shares.
12. LITIGATION AND CONTINGENCIES
There are various litigation proceedings in which the Company and its
subsidiaries are involved. Many of the claims asserted against the
Company in these proceedings are covered by insurance. The results of
litigation proceedings cannot be predicted with certainty. However, in
the opinion of the Company's general counsel, such proceedings either
are without merit or do not have a potential liability which would
materially affect the financial condition of the Company and its
subsidiaries on a consolidated basis.
13. BUSINESS SEGMENTS
In 1997, SFAS No. 131 was issued, "Disclosures about Segments of an
Enterprise and Related Information". SFAS No. 131 requires disclosure of
certain information about segments of an enterprise.
The Company is currently in two different business segments: The
compounding, dispensing, and distribution of radiopharmaceuticals, and
the management and provision of medical diagnostic imaging services.
Prior to 1998, the Company only participated in the radiopharmaceuticals
segment.
<TABLE>
<CAPTION>
PHARMACY SERVICES BUSINESS 1998
________________________________________________________________________
<S> <C> <C> <C>
Revenues $411,531
Operating Income $ 34,210
Total Assets $120,451
Capital Expenditures $ 8,173
Depreciation/Amortization $ 6,814
MEDICAL IMAGING BUSINESS 1998
________________________________________________________________________
___
Revenues $ 37,492
Operating Income $ 3,196
Total Assets $ 94,504
Capital Expenditures $ 2,717
Depreciation/Amortization $ 4,941
UNALLOCATED CORPORATE 1998
________________________________________________________________________
Operating Loss $(12,856)
Total Assets $ 41,612
Capital Expenditures $ 5,096
Depreciation/Amortization $ 3,472
GEOGRAPHIC SEGMENTS REVENUES OPERATING TOTAL
INCOME ASSETS
________________________________________________________________________
Unites States
1998 $438,479 $25,154 $239,825
1997 $373,661 $13,871 $151,444
1996 $361,411 $ 8,961 $138,785
Rest of World
1998 $ 10,544 $ (604) $ 16,742
1997 $ 6,902 $ (859) $ 13,119
1996 $ 5,036 $ (304) $ 6,778
________________________________________________________________________
</TABLE>
INDEPENDENT AUDITORS' REPORT
THE BOARD OF DIRECTORS AND STOCKHOLDERS, SYNCOR INTERNATIONAL CORPORATION
We have audited the accompanying consolidated balance sheets of
Syncor International Corporation and subsidiaries as of December 31,
1998 and 1997, and the related consolidated statements of income,
stockholders' equity and comprehensive income and cash flows for each of
the years in the three-year period ended December 31, 1998. These
consolidated financial statements are the responsibility of the
Company's management. Our responsibility is to express an opinion on
these consolidated financial statements based on our audits.
We conducted our audits in accordance with generally accepted
auditing standards. Those standards require that we plan and perform the
audit to obtain reasonable assurance about whether the financial
statements are free of material misstatement. An audit includes
examining, on a test basis, evidence supporting the amounts and
disclosures in the financial statements. An audit also includes
assessing the accounting principles used and significant estimates made
by management, as well as evaluating the overall financial statement
presentation. We believe that our audits provide a reasonable basis for
our opinion.
In our opinion, the consolidated financial statements referred to
above present fairly, in all material respects, the financial position
of Syncor International Corporation and subsidiaries as of December 31,
1998 and 1997, and the results of their operations and their cash flows
for each of the years in the three-year period ended December 31, 1998,
in conformity with generally accepted accounting principles.
/s/ KPMG LLP
__________________________
KPMG LLP
Los Angeles, California
February 22, 1999
MANAGEMENT'S REPORT
The Management of Syncor International Corporation is responsible for
the consolidated financial statements and all other information
presented in this report. The consolidated financial statements have
been prepared in conformity with generally accepted accounting
principles appropriate in the circumstances and, therefore, included in
the consolidated financial statements are certain amounts based on
management's informed estimates and judgments. Management is responsible
for establishing and maintaining a system of internal control designed
to provide reasonable assurance as to the integrity and reliability of
financial reporting. The concept of reasonable assurance is based on the
recognition that there are inherent limitations in all systems of
internal control, and that the cost of such systems should not exceed
the benefits to be derived therefrom. Other financial information in
this report is consistent with that in the consolidated financial
statements. The consolidated financial statements have been examined by
Syncor International Corporation's independent certified public
accountants and have been reviewed by the Audit Committee of the Board
of Directors.
<TABLE>
<CAPTION>
SELECTED QUARTERLY RESULTS OF OPERATIONS
The unaudited quarterly operating results in the Selected Quarterly Results
of Operations have been prepared on the same basis as the audited
consolidated financial statements and, in the opinion of management, include
all adjustments necessary for a fair presentation for the periods presented.
Unaudited calendar quarterly information is summarized below:
(IN THOUSANDS, EXCEPT PER SHARE DATA) MARCH 31, JUNE 30, SEPTEMBER 30, DECEMBER 31, 1998
______________________________________________________________________________________________________
<S> <C> <C> <C> <C> <C>
Net sales $102,724 $113,245 $114,102 $118,952 $449,023
Gross profit $ 27,155 $ 34,592 $ 34,866 $ 35,337 $131,950
Net income from continuing operations $ 3,358 $ 4,395 $ 2,726 $ 3,452 $ 13,931
Net income per share from continuing operations:
Basic $ 0.33 $ 0.42 $ 0.25 $ 0.31 $ 1.30
Diluted $ 0.31 $ 0.40 $ 0.24 $ 0.29 $ 1.23
Net income $ 3,358 $ 4,395 $ 2,726 $ 3,452 $ 13,931
Net income per share:
Basic $ 0.33 $ 0.42 $ 0.25 $ 0.31 $ 1.30
Diluted $ 0.31 $ 0.40 $ 0.24 $ 0.29 $ 1.23
Weighted average shares outstanding:
Basic 10,304 10,536 10,982 11,073 10,726
Diluted 10,786 11,057 11,504 11,960 11,339
=======================================================================================================
Market price per share
High $ 18.94 $ 18.38 $ 19.88 $ 27.25 $ 27.25
Low $ 13.81 $ 15.50 $ 14.00 $ 14.50 $ 13.81
=======================================================================================================
(IN THOUSANDS, EXCEPT PER SHARE DATA) MARCH 31, JUNE 30, SEPTEMBER 30, DECEMBER 31, 1997
_______________________________________________________________________________________________________
Net sales $ 93,084 $ 98,187 $ 94,493 $ 94,799 $380,563
Gross profit $ 20,116 $ 23,854 $ 22,260 $ 23,935 $ 90,165
Net income from continuing operations $ 3,346 $ 3,237 $ 1,754 $ 1,695 $ 10,032
Net income per share from continuing operations:
Basic $ 0.33 $ 0.33 $ 0.18 $ 0.17 $ 1.00
Diluted $ 0.32 $ 0.33 $ 0.17 $ 0.16 $ 0.98
Net income $ 3,346 $ 4,300 $ 1,754 $ 1,695 $ 11,095
Net income per share:
Basic $ 0.33 $ 0.44 $ 0.18 $ 0.17 $ 1.11
Diluted $ 0.32 $ 0.44 $ 0.17 $ 0.16 $ 1.08
Weighted average shares outstanding:
Basic 10,168 9,829 9,920 10,074 9,998
Diluted 10,359 9,870 10,323 10,574 10,282
=======================================================================================================
Market price per share:
High $ 13.63 $ 10.88 $ 17.25 $ 17.44 $ 17.44
Low $ 8.63 $ 7.50 $ 10.13 $ 14.88 $ 7.50
=======================================================================================================
</TABLE>
BOARD OF DIRECTORS
Monty Fu
Chairman of the Board
Director since 1985
Robert G. Funari
President and
Chief Executive Officer
Director since 1995
George S. Oki
Chairman of the Board,
Meta Information Services, Inc.
Director since 1985
Audit Committee
Arnold E. Spangler
Managing Director,
Mancuso & Company
Director since 1985
Audit Committee, Compensation
Committee
Steven B. Gerber, MD
Managing Director,
CIBC Oppenheimer Corp.
Director since 1990
Audit Committee, Compensation
Committee
Henry N. Wagner, Jr., MD
Professor of Radiological Science
Director of Nuclear Medicine
The Johns Hopkins Medical
Institutions
Director since 1992
Gail R. Wilensky, PhD
Senior Fellow, Project HOPE,
former HCFA Administrator and
Deputy Assistant to President Bush
Director since 1993
Compensation Committee
Ronald A. Williams
President,
Blue Cross of California
Director since 1998
OFFICERS
Monty Fu
Chairman of the Board
Robert G. Funari
President and
Chief Executive Officer
Brad Nutter
Executive Vice President and
Chief Operating Officer
Haig S. Bagerdjian
Executive Vice President, Secretary and Chief Legal Officer, President and
Chief Executive Officer
Syncor Overseas Ltd.
David L. Ward
President and Chief
Executive Officer
Comprehensive Medical
Imaging, Inc.
Michael E. Mikity
Senior Vice President and
Chief Financial Officer
John S. Baumann
Corporate Vice President and
General Counsel
Jack L. Coffey
Corporate Vice President,
Quality and Regulatory
Sheila H. Coop
Corporate Vice President,
Human Resources
STOCKHOLDER INFORMATION
INQUIRIES
Stockholders, interested investors and investment professionals are invited
to contact the Company for further information throughout the year.
The Company also has available a news-on-demand service whereby individuals
can obtain information via facsimile. Individuals may call (800) 546-8172
to obtain press releases and other related information via facsimile.
WEB SITE
www.syncor.com
ANNUAL MEETING
The Company's Annual Meeting of Stockholders will be held at 1:00 pm,
Wednesday, June 23, 1999, at the Warner Center Hilton Hotel, 6360 Canoga
Avenue, Woodland Hills, California 91367. Stockholders of record on April
26, 1999, are invited to attend and vote at that meeting.
FORM 10-K
To receive a copy of the Company's Annual Report on Form 10-K filed with
the Securities and Exchange Commission, contact the Corporate Headquarters,
Syncor International Corporation, Attn: Investor Relations Department, 6464
Canoga Avenue, Woodland Hills, California 91367.
INDEPENDENT AUDITORS
KPMG LLP, 725 South Figueroa Street, Los Angeles, California 90017
STOCK DATA
The Company's common stock is quoted on the National Association of
Securities Dealers Automated Quotation System (NASDAQ) under the symbol
SCOR.
TRANSFER AGENT AND REGISTRAR
Stockholders wishing to report a change of address, may forward details,
including both the old and new addresses, to:
American Stock Transfer & Trust Company
40 Wall Street, 46th Floor
New York, New York 10015
(212) 936-5100
STOCK MARKET INFORMATION
Stock price quotations are printed daily in major newspapers, including the
Wall Street Journal. As of March 24, 1999, there were 11,614,670 shares of
common stock outstanding. Stockholders of record at that date numbered to
1,064. The Company has not paid cash dividends on its stock and has no
current intention of paying cash dividends in the foreseeable future.
<PAGE>
Exhibit 23
INDEPENDENT AUDITORS' CONSENT
The Board of Directors and Stockholders
Syncor International Corporation
The audits referred to in our report dated February 22, 1999 included the
related financial statement schedule for each of the years in the three-
year period ended December 31, 1998, included in the registration statement
of Syncor International Corporation. This financial statement schedule is
the responsibility of the Company's management. Our responsibility is to
express an opinion on this financial statement schedule based on our
audits. In our opinion, such financial statement schedule, when considered
in relation to the basic consolidated financial statements taken as a
whole, presents fairly in all material respects the information set forth
therein.
We consent to incorporation by reference in the registration statements
(Nos. 33-7325, 33-39251, 33-57762, 33-52607, 333-18373, 333-18375, 333-18377,
333-3999, 333-40117, 333-62091, 333-62093, and 333-68277) on From S-8 of
Syncor International Corporation of our report dated February 22, 1999
relating to the consolidated balance sheets of Syncor International
Corporation and subsidiaries as of December 31, 1998 and 1997 and the
related consolidated statements of income, stockholders' equity and cash
flows and related schedule for each of the years in the three-year period
ended December 31, 1998, which report appears in the December 31, 1998
annual report on Form 10-K of Syncor International Corporation.
/s/ KPMG LLP
Los Angeles, California
March 29, 1999
<PAGE>
Exhibit 27
FINANCIAL DATA SCHEDULE
<TABLE>
<CAPTION>
<S> <C>
PERIOD TYPE 12 mos
FISCAL YEAR END 12/31/98
PERIOD START 1/1/98
PERIOD END 12/31/98
CASH 18,531
SECURITIES 1,191
RECEIVABLES 79,553
ALLOWANCES (3,774)
INVENTORY 11,495
CURRENT ASSETS 118,585
PP&E 98,041
DEPRECIATION (48,938)
TOTAL ASSETS 256,567
CURRENT LIABILITIES 74,561
BONDS 0
PREFERRED MANDATORY 0
PREFERRED 0
COMMON 626
OTHER SE 110,747
TOTAL LIABILITY AND EQUITY 256,567
SALES 449,023
TOTAL REVENUE 449,023
CGS 317,073
TOTAL COSTS 317,073
OTHER EXPENSES 107,400
LOSS PROVISION 0
INTEREST EXPENSE (5,291)
INCOME PRE TAX 24,185
INCOME TAX 10,254
INCOME CONTINUING 13,931
DISCONTINUED 0
EXTRAORDINARY 0
CHANGES 0
NET INCOME 13,931
EPS BASIC 1.30
EPS DILUTED 1.23
</TABLE>
